Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  1 CONFIDENTIAL  RZL -012 Study Protocol  
Protocol Number  RZL -012-P2aUS -001.4 
 
A Double Blind, Randomized, Placebo Controlled, Dose Escalation Phase 2a Clinical Trial 
for the Evaluation of Safety and Thermogenesis -induction of RZL -012 in Overweight and 
Obese Volunteers  
Principal Investigator:  
[INVESTIGATOR_458062] , MD  
Sponsor:  
Raziel Therapeutics LTD  
Hadassah Ein -Karem, JBP building, P.O.B. [ADDRESS_631855] and/or Regulatory Authority under the condition that 
confidentiality is maintained  
 
Protocol Date:  11 July  2017 
Version 1:  20 February 2017 
Version 1.1:  26 May  2017 
Version 1.2 : 11 July 2017  
Version 1.3: 20Aug 2017  
Version 1.4: 4 March  2018  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631856] OF ABBREVIATION S ................................ ................................ ................................ .......... 8 
STATEMENT OF COMPLIA NCE  ................................ ................................ ............................... 11 
INVE STIGATOR SIGNATURE P AGE  ................................ ................................ ....................... 12 
PROTOCOL SYNOPSIS  ................................ ................................ ................................ .............. 13 
1. INTRODUCTION  ................................ ................................ ................................ ......21 
1.1. BACKGROUND  ................................ ................................ ................................ ........ 21 
1.1.1.  Scientific Background and Clinical Rationale  ................................ ............................ 21 
1.1.2.  RZL -012 Formulation Development  ................................ ................................ .......... 23 
1.2. NONCLINICAL ASSESSMENTS  ................................ ................................ ............ 24 
1.2.1.  Pharmacology  ................................ ................................ ................................ ............. 24 
[IP_ADDRESS].  Efficacy In -vivo and In -vitro Studies  ................................ ................................ ......... 24 
[IP_ADDRESS].  Safety Pharmacology  ................................ ................................ ................................ ..24 
1.2.2.  Toxicology  ................................ ................................ ................................ .................. 25 
[IP_ADDRESS].  Extended Single Dose Toxicity Studies  ................................ ................................ .....25 
1.2.3.  Additional Nonclinical Studies  ................................ ................................ ................... 27 
1.2.4.  Clinical Studies  ................................ ................................ ................................ ........... 27 
2. PURPOSE AND STUDY OB JECTIVES  ................................ ................................ ..30 
2.1. PURPOSE  ................................ ................................ ................................ ................... 30 
2.2. STUDY OBJEC TIVES  ................................ ................................ .............................. 30 
2.2.1.  Primary  ................................ ................................ ................................ ....................... 30 
2.2.2.  Secondary  ................................ ................................ ................................ ................... 30 
3. STUDY DESIGN  ................................ ................................ ................................ .......31 
3.1. DESCRIPTION OF STUDY DESIGN  ................................ ................................ ......31 
3.2. DOSE RATIONALE  ................................ ................................ ................................ ..31 
3.3. DOSING  ................................ ................................ ................................ ..................... 31 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631857] IDENTIFICATION  ................................ ................................ .................. 36 
5.4. REMOVAL, REPLACEMENT OR EARLY WITHDRAWAL OF 
SUBJECTS FROM ASSESSMENT NOT DUE TO INTOLERABLE SIDE 
EFFECTS  ................................ ................................ ................................ .................... 36 
6. STUDY PROCEDURES AND ASSES SMENT  ................................ ........................ 37 
6.1. DEFINITIONS OF STUDY PROCEDURES  ................................ ............................ 37 
6.1.1.  Informed Consent  ................................ ................................ ................................ .......37 
6.1.2.  Medical History  ................................ ................................ ................................ .......... 37 
6.1.3.  Concomitant Medication  ................................ ................................ ............................ 38 
6.1.4.  Physical Examination  ................................ ................................ ................................ .38 
6.1.5.  Vital Signs and Measurements  ................................ ................................ ................... 38 
6.1.6.  Anthropometric Measurements  ................................ ................................ .................. 38 
[IP_ADDRESS].  Weight  ................................ ................................ ................................ ......................... 39 
[IP_ADDRESS].  Height ................................ ................................ ................................ ......................... 39 
[IP_ADDRESS].  BMI  ................................ ................................ ................................ ............................. 40 
[IP_ADDRESS].  Waist Circumference  ................................ ................................ ................................ ..40 
[IP_ADDRESS].  Hip Circumference  ................................ ................................ ................................ ......40 
[IP_ADDRESS].  Waist to Hip Ratio (WHR)  ................................ ................................ ......................... 41 
6.1.7.  Serology Assays  ................................ ................................ ................................ .......... 41 
6.1.8.  Clinical Laboratory Tests  ................................ ................................ ........................... 41 
[IP_ADDRESS].  Hematology  ................................ ................................ ................................ ................. 41 
[IP_ADDRESS].  Serum Chemistry Analysis  ................................ ................................ ......................... 42 
[IP_ADDRESS].  Urine Drug Screen  ................................ ................................ ................................ ......42 
[IP_ADDRESS].  Inflammatory Markers and Cytokines  ................................ ................................ ........ 42 
[IP_ADDRESS].  Histamine  ................................ ................................ ................................ .................... 43 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  4 CONFIDENTIAL  [IP_ADDRESS].  Urinalysis  ................................ ................................ ................................ .................... 43 
6.1.9.  ECG  ................................ ................................ ................................ ............................ 43 
6.1.10.  Draize Sco re ................................ ................................ ................................ ................ 44 
6.1.11.  Photography of the Injected Site  ................................ ................................ ................. 44 
6.1.12.  Thermal Imaging  ................................ ................................ ................................ ........ 45 
6.1.13. Fat Tissue Imaging: Magnetic Resonance Imaging (MRI)  ................................ ........ 45 
6.1.14.  Biopsy  ................................ ................................ ................................ ......................... 46 
6.1.15.  Pharmacokinetics  ................................ ................................ ................................ ........ 47 
6.1.16.  Adverse Events  ................................ ................................ ................................ ........... 48 
6.1.17 . Evaluation of Response  ................................ ................................ .............................. 48 
[IP_ADDRESS].  Evaluation of Primary Endpoints ................................ ................................ ................ 48 
[IP_ADDRESS].  Evaluation of Secondary Endpoints ................................ ................................ ............ 49 
[IP_ADDRESS].  Compliance Monitoring  ................................ ................................ .............................. 50 
[IP_ADDRESS].  Dispensing of RZL -[ADDRESS_631858]  ................................ ........................ 50 
[IP_ADDRESS].  Questioning of Study Subjects  ................................ ................................ .................... 50 
6.2. STUDY VISITS ................................ ................................ ................................ .......... 51 
6.2.1.  Screening Procedures  ................................ ................................ ................................ ..51 
6.2.2.  Study Randomization  ................................ ................................ ................................ ..52 
6.2.3.  Study Treatment  ................................ ................................ ................................ .......... 52 
6.2.3. 1. Treatment with RZL -012 Investigational Therapy  ................................ ..................... 52 
[IP_ADDRESS].  Treatment with Placebo  ................................ ................................ .............................. [ADDRESS_631859] Site Visits  ................................ ................................ ................................ .......56 
6.2.6. Termination Visit  ................................ ................................ ................................ ........ 57 
6.2.7.  Unscheduled Visit  ................................ ................................ ................................ .......57 
7. SAFETY CONSIDERATION S AND GUIDANCE FOR 
INVESTIGATORS  ................................ ................................ ................................ .....57 
7.1. STUDY RESTRICTIONS REGARDING CONCOMITANT 
MEDICATIONS  ................................ ................................ ................................ ......... 57 
7.2. SAFETY MEASUREMENTS ................................ ................................ .................... 57 
7.3. PREMATURE DISCONTINUATION FROM STUDY ................................ ............ 59 
7.4. PREMATURE STUDY TERMINATION  ................................ ................................ .59 
7.5. DEVIATION FROM STUDY PROTOCOL ................................ .............................. 59 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631860] AND VEHICLE SPEC IFICATIONS  ................ 60 
8.1. DESCRIPTION OF RZL -012 ................................ ................................ .................... 60 
8.2. FORMULATION, PACKAGING AND LABELING  ................................ ............... 60 
8.3. STORAGE AND STABILITY OF RZL -012 AND VEHICLE  ................................ .60 
8.4. DOSAGE, DISPENSING AND ADMINISTRATION OF RZL -012 AND 
VEHICL E ................................ ................................ ................................ ................... 60 
8.4.1.  Dosage  ................................ ................................ ................................ ........................ 60 
8.4.2.  Administration and Instructions for Use  ................................ ................................ .....61 
8.5. ACCOUNTABILITY OF RZL -012 AND VEHICLE  ................................ ............... 61 
9. ADVERSE EVENTS ................................ ................................ ................................ ..62 
9.1. ADVERSE EVENT DEFINITIONS  ................................ ................................ .......... 62 
9.1.1.  Definition of Adverse Event (AE)  ................................ ................................ .............. 62 
9.1.2.  Definition of Serious Adverse Event  ................................ ................................ .......... 62 
9.1.3.  Definition of Adverse Drug Reaction  ................................ ................................ ......... 62 
9.2. ADVERSE EVENT GRADING  ................................ ................................ ................ 62 
9.3. CA[LOCATION_003]LITY ASSESSMENT OF ADVERSE EVENTS (AEs)  ............................... 63 
9.4. UNEXPECTEDNESS OF ADVERSE DRUG REACTIONS  ................................ ...64 
9.5. ADVERSE EVENT REPORTING AND MONITORING 
REQUIREMENTS  ................................ ................................ ................................ .....65 
9.5.1.  General  ................................ ................................ ................................ ........................ 65 
9.5.2.  SAE Reporting  ................................ ................................ ................................ ............ 65 
9.5.3.  Expedited Reporting  ................................ ................................ ................................ ...66 
10. STATISTICAL CONSIDER ATIONS  ................................ ................................ .......66 
10.1.  STUDY DESIGN AND OBJECTIVE  ................................ ................................ .......66 
10.2.  STUDY ENDPOINTS  ................................ ................................ ................................ 67 
10.2.1.  Primary Safety Endpoint  ................................ ................................ ............................. 67 
10.2.2.  Primary Efficacy Endpoint  ................................ ................................ ......................... 67 
10.2.3.  Secondary Efficacy Endpoints  ................................ ................................ .................... 67 
10.2.4.  Safety and Tolerability Endpoints  ................................ ................................ .............. 68 
10.3.  SAMPLE SIZE JUSTIFICATION  ................................ ................................ ............. 68 
10.4.  ANALYSIS SETS  ................................ ................................ ................................ ......69 
10.4.1.  Safety Analysis Set (SA)  ................................ ................................ ............................ 69 
10.4.2.  Efficacy Analysis Set (EF)  ................................ ................................ ......................... 69 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  6 CONFIDENTIAL  10.4.3.  PK (PKA) Analysis Set  ................................ ................................ .............................. [ADDRESS_631861] Disposition  ................................ ................................ ................................ .....70 
10.5.3.  Demographic and Baseline Characteristics  ................................ ................................ 70 
10.5.4.  Primary Safety Endpoint  ................................ ................................ ............................. 70 
10.5.5.  Efficacy Analysis  ................................ ................................ ................................ ........ 70 
10.5.6.  Pharmacokinetics (PK) Assessment  ................................ ................................ ........... [ADDRESS_631862] KEEPI[INVESTIGATOR_1645]  ................................ ................................ ................................ ..73 
11.3.  SOURCE  DATA AND SOURCE DOCUMENTS  ................................ .................... 73 
11.4.  STUDY MONITORING  ................................ ................................ ............................ 73 
11.5.  CONFIDENTIALITY, DATA DISCLOSURE, AND PUBLICATION  ................... 74 
12. HUMAN SUBJECTS  ................................ ................................ ................................ .75 
12.1.  DECLARATION OF HELSINKI  ................................ ................................ .............. 75 
12.2.  INFORMED CONSENT  ................................ ................................ ............................ 75 
12.2.1.  LIABILITY AND INSURANCE CONDITIONS  ................................ ...................... 75 
13. REFERENCES  ................................ ................................ ................................ ........... 75 
 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631863] OF TABLES  
Table 1:  Phase 0 Clinical Trial Design  ................................ ................................ ......................... 28 
Table 2:  Subject Information an d Timeframes  ................................ ................................ ............. 55 
Table 3:  RZL -012 and Vehicle Storage Conditions  ................................ ................................ .....60 
Table 4:  Definition of Causality  ................................ ................................ ................................ ...[ADDRESS_631864] OF FIGURES  
Figure 1:  MRI: Distribution of 16 Consecutive Slices  ................................ ................................ .46 
Figure 2:  Biops y Site and Dimensions ................................ ................................ .......................... 47 
Figure 3:  RZL -012 Injection Sites  ................................ ................................ ................................ 53 
Figure 4:  Design of the [ADDRESS_631865] OF APPE NDICES  
Appendix I:  Trial Schedule of Events  ................................ ................................ ........................... 77 
 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631866]  Aspartate aminotransferase  
ATP  Adenosine triphosphate  
AUC  Area under the concentration -time curve  
BAT  Brown -like adipose tissue  
BMI  Body Mass Index  
BUN  Blood urea nitrogen  
°C Degrees Celsius  
CBC  Complete blood count  
CDC  Center for Disease Control  
cGMP  Current Good Manufacturing Practices  
CI Confidence Interval  
CK-MM Creatine  Kinase - Muscle  
Cmax Maximum observed concentration  
CNS  Clinically not significant  
CRF  Case Report Form  
CPK  Creatine phosphokinase  
CRP  C-reactive protein  
CS Clinically significant  
CTC  Common terminology criteria  
CTCAE  Common Terminology Criteria for Adverse Events  
DICOM  Digital Imaging and Communications in Medicine  
DSMB  Data and Safety Monitoring Board  
EC Ethics Committee  
ECG  Electrocardiogram  
EF Efficacy analysis  set 
ER Emergency room  
FDA  Food and Drug Administration  
FFA Free fatty acids  
FIFO  First In First Out  
FLASH  Fast-low-angle shot  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631867] Term  Explanation  
FOB  Functional Observational Battery  
GLP  Good Laboratory Practice  
GTT P Gamma -glutamyltransferase  
HBV  Hepatitis B virus  
HCRC  Hadassah Clinical Research Center  
HCV  Hepatitis C virus  
H&E  Hematoxylin and eosin stain  
HDL  High -density lipoprotein  
HED  Human equivalent dose  
HIV Human immunodeficiency virus  
IC50 Half maximal inhibitory concentration  
ICF Informed Consent Form  
ICH-GCP  International Conference on Harmonization Good Clinical 
Practice  
IFN Interferon  
IL Interleukin  
INR International normalized ratio  
IRB Institutional Review Board  
LDL  Low-density lipoprotein  
LDH  Lactate dehydrogenase  
LPL Lipoprotein lipase  
MCH  Mean corpuscular hemoglobin  
MCHC  Mean corpuscular hemoglobin concentration  
MCP  Monocyte chemoattractant protein  
MCV  Mean corpuscular volume  
MD Medical Doctor  
MPV  Mean platelet volume  
MRI  Magnetic Resonance Imaging  
NHANES  National Health and Nutrition Examination Survey  
NOAEL  No observed adverse  effect level  
NSAIDs  Non Steroid Anti -Inflammatory Drugs  
PI [INVESTIGATOR_491374] , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631868] Term  Explanation  
RBC  Red blood cells 
RDW  Red cell distribution width  
SA Safety analysis set  
SAE  Serious adverse event  
SAT  Subcutaneous adipose tissue  
SC Subcutaneous  
SFM  Subcutaneous fat mass  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
T1/[ADDRESS_631869]  Upper limit of normal  
US/[LOCATION_003]  [LOCATION_002]/[LOCATION_002] of America  
WAT  White adipose tissue  
WBC  White blood cells  
WHR  Waist to hip ratio  
 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  11 CONFIDENTIAL  STATEMENT OF COMPLIA NCE  
This clinical trial will be conducted in compliance with the protocol, International Conference on 
Harmonization Good Clinical Practice E6 and the applicable regulatory requirements.  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631870] read and understood the protocol and agree to implement the study in accordance with the 
procedures set forth in the protocol and in acco rdance with the Sponsor's guidelines, all 
applicable government regulations and the International Conference on Harmonization Good 
Clinical Practice Guidelines E6 (ICH -GCP).  
I will provide adequate protocol training to my associates, colleagues and employe es assisting in 
the conduct of the study.  
I will obtain Institutional Biosafety Committee (or equivalent) and Institutional Review Board 
(IRB)/Ethics Committee (EC) approval of the protocol and the Subject Informed Consent form 
prior to enrollment of subj ects in the study.  I understand that any modifications to the protocol 
made during the course of the study must first be approved by [CONTACT_491397] (or equivalent) and IRB/EC except when such modification is made to remove an 
immedi ate hazard to the subject.  
I will ensure that a fully executed Subject Informed Consent form is obtained from each subject 
prior to initiation of any study procedures.  
I will report (within 24 hours) any serious adverse event that occurs during the cours e of the 
study in accordance with the procedures described in Section 9 of the protocol.  
I will allow the S ponsor, Raziel Therapeutics Ltd. and it s agents, as well as the [LOCATION_002] 
(US) Food and Drug Administration (FDA) and other regulatory agencies, to inspect study 
facilities and pertinent records at reasonable times and in a reasonable manner, ensuring subject 
confidentiality .  If I am notif ied that this study is to be inspected by a regulatory agency, I will 
notify the Sponsor as soon as possible thereafter (no later than one week).  
 
 
 
 
_____________________  ____________________    _____________________  
Investigator's name    [CONTACT_10670]’s Signature    [CONTACT_491466] , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  13 CONFIDENTIAL  PROTOCOL SYNOPSIS  
Protocol 
Number  RZL -012-P2aUS -001.2 
Protocol Title  A Double Blind, Randomized, Placebo Controlled, Dose Escalation Phase 2a Clinical Trial for the 
Evaluation of Safety and Thermogenesis -induction of RZL -012 in Overweight and Obese Volunteers   
Study Phase  Phase 2a 
Study Drug  RZL -012 
Study 
Objectives  Primary objective :  Evaluation of the overall safety  and preliminary efficacy  of RZL -012 after 
injection  into the subcutaneous fat .  
Secondary objective :  Determination of RZL -[ADDRESS_631871] and the extent, duration and tissue associated 
changes of the thermogenic response to RZL -012, via minimal invasive means (injected -site 
thermogenesis imaging, Magnetic Re sonance Imaging (MRI) and biopsy) after subcutaneous 
injection into fatty tissue below the skin.  
Sample Size  32 subjects  
Study Design  This is a consecutive  4 cohort, dose escalation placebo -controlled clinical trial  in overweight and 
obese subjects .  All cohorts will be comprised of 6 active (RZL -012) and [ADDRESS_631872] ( DSMB ).  The decision to proceed to the next cohort will be 
made after reviewing all safety data collected by [CONTACT_2006] 14 within 2 ± 1d of the last dosed subject in 
each cohort .  If two (2) intolerable side effects are observed in any dose cohort, further treatment at 
that dose will be stopped and only to lerable doses used for further subjects.  
The DSMB will be comprised of two independent MDs expert in early phase clinical trials.  
Study 
Population  20-60 years old, overweight and obese by [CONTACT_296306] (BMI) definition ( 27.5 < BMI ≤ 34.9), 
adult males.  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631873] meet all the following to be eligible for study participation:  
1. Adult male subjects, [ADDRESS_631874] is considered overweight  and obese , with 27.5 < BMI ≤ 34.9. 
3. Significant subcutaneous abdominal fat as defined by [CONTACT_491398] (WHR) ≥  0.9.   
4. Subjects with stable weight in the last [ADDRESS_631875]'s declaration: anorexia nervosa, bulimia 
nervosa.  
6. Generally considered h ealthy according to medical history, physical examination, 
electrocardiogram (ECG) and laboratory evaluation with a special emphasis on metabolic 
parameters (fasting glucose concentration <  100 mg, normal blood pressure).  
7. Subject is willing to refrain from  sexual activity or agrees to use a double -barrier contraceptive 
device (e.g., condom  and spermicide ) for [ADDRESS_631876] sign an informed consent indicating that they are aware of the investigational 
nature of the study.  
Main Exclusion 
Criteria  Subjects meeting any of the following criteria will be excluded:  
1. Subjects weighing less than [ADDRESS_631877] reduced/gained weight more than 5% of their current body weight in the last 
3 months.  
3. Unable to tolerate subcutaneous injection.  
4. Subjects with uncontrolled cardiac, hepatic, renal or neurologic/psychia tric disorders, that in the 
opi[INVESTIGATOR_491375], are not eligible.  
5. Subjects who test positive to either Hepatitis B virus (HBV), Hepatitis C virus (HCV), or Human 
immunodeficiency virus (HIV) are not eligible.  
6. Subjects with a clinical history of primary or secondary immunodeficiency, autoimmune disease 
or subjects taking immunosuppressive drugs such as corticosteroids are ineligible.  
7. As a result of medical review, physical examination, the PI (or medically quali fied nominee) 
considers the subject unfit for the study.  
8. Medication use on regular basis  including blood and blood products . 
9. Positive drug and alcohol tests.  
10. Known sensitivity to components of the injection formulation.  
11. Prior wound, tattoo or infection in  the treated area.  
12. Excessive growth of hair in the abdomen region.  
13. Claustrophobia or MRI incompatible device or implant.  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631878]  define d as any of the following treatment -related adverse drug reactions 
(ADRs):  
• Any Grade 3 or greater  event except for the following  (For the following entities, a 
discussion will be held by [CONTACT_978], DSMB and Sponsor to decide whether considered 
as:intolerable side effects ): 
o Flu-like symptoms and fever that responds to standard treatment within 72 hours  
o Localized edema and erythema  
o Pruritus  
o Pain 
o Skin/soft tissue inflammation  
o Fat Atrophy  
o Liver enzymes abnormality  
o Non-significant lab abnormalities, lasting less than 7 days  (see Section 3.3.2 ) 
Study discontinuation is to be considered by [CONTACT_491399] , 
and the actions taken are to be fully documented in source documents and Case Report Forms 
(CRFs).  
To be considered a n intolerable side effect , such  an event  must be considered to be possibly or 
probably related to the study drug  
Subjects experiencing an intolerable side effect  will be withdrawn from the study, but followed for 
toxicity.  
The study may also  be prematurely terminated in any of the  follo wing cases:  
• Recurring serious or severe adverse drug reaction ( ADR ) clinically evaluated by [CONTACT_491400].  
• A decision made by [CONTACT_166327]/or IRB/EC and/or local regulatory agency to terminate the 
study.  
Study Drug 
Dosage and 
Administration  Subjects will receive single doses of the investigational product (RZL -012) or the placebo  in 
accordance with the following:  
 Cohort 1  Cohort 2  Cohort 3  Cohort 4  
Number of Subjects – 
Active/Placebo  6/2 6/2 6/2 6/2 
Total Dose RZL -012 
(mg)  40 80 120 180 
Dose per NOAEL*  1/6.25th  1/3.125th  1/2.34th  1/1.39 
Number of Injections  8 16 24 36 
* based on Human Equivalent Dose (HED) from GLP toxicology study)  
The initial dose will be 40 mg RZL -012 (1/ 6.25th the no observed adverse  effect level  (NOAEL ) 
based on Human Equivalent Dose (HED) from GLP toxicology study) with subsequent doses of 
80 mg and 120 mg (1/ 3.125th and 1/2.34h the NOAEL based on HED) .  The final dose will be 180 mg 
RZL -012, (1/1. 39the NOAEL  based on HED) .  Subjects  will receive a single treatment in multiple 
sites ( 8-48) of injection diagonally (45  °) to the skin surface at 5 cm lateral to the umbilicus  lateral 
wall.  The distance between injected sites will be 2 cm (see pi[INVESTIGATOR_50615])  in the first three cohorts 
and 1cm in the fourth cohort . 
The first cohort of 6 subjects will receive 8 injection s (0.1 mL  each in a 2  x 4 cluster and 2 cm apart ) 
of 40 mg RZL -012 (~1/ 6.25th of the NOAEL) .  Additional 2 subjects in the cohort will serve as  
control and will be injected placebo (vehicle).  
If no more than [ADDRESS_631879] , according to schedule and following the DSMB approval an additional cohort 
(Cohort 2) of six volunteers, as above, will receive 16 injections (0.1 mL each in a 4 x4 cluster and 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  16 CONFIDENTIAL  2 cm apart) adding up to 80 mg RZL -012 (~1 /3.125th of the NOAEL).  Additional 2 subjects in the 
cohort  will serve as control and will be injected placebo (vehicle) .  
If no more than [ADDRESS_631880]  according to schedule and following the DSMB approval , an additional cohort 
(Cohort 3) of six volunteers will receive a cluster of 24 injections (0.1 mL each in a 6x4 cluster  and 2 
cm apart ) adding up to 120 mg RZL -012 (~1/ 2.34th of the NOAEL) .  Additional 2 subjects in the 
cohort will serve as control and w ill be injected placebo (vehicle).   
If no more than [ADDRESS_631881] according to schedule and following the DSMB approval an additional cohort 
(Cohort 4) of six volunteers, as above, will receive 36 injections (0.1 mL each in a 9x4 cluster and 
1cm apart ) adding up to 240 mg RZL -012 (~1/1. 39 of the NOAEL) .. Additional 2 subjects in the 
cohort will serve as control and will be injected placebo (vehicle).  
 
 
 
Concomitant 
Medication  All concomitant medication given 3 months prior to study entry, including blood and blood products, 
dietary supplements, and non -prescription drugs will be listed at screening/baseline.  The clinical 
significance of the medication us e will be decided by [CONTACT_093].  Study subjects will be 
routinely questioned for changes in the administration of concomitant medication during the trial.  
Subjects may not receive the following medications while on study:  
• Chronic treatment with sy stemic steroids or immunosuppressive drugs .  
• Chronic treatment with Non Steroid Anti -Inflammatory Drugs (NSAIDs).  
• Any investigational product other than RZL -012.  
Before dosing, analgesic gels or creams such Lidocaine (e.g., Emla) or Pramoxine should be u sed to 
numb the injected site .  An ice pack may be applied on the site of injection following dosing to help 
reduce pain .  At day 3 following blood sampling for histamine, the anti -histamine Benadryl Gel 
(Dimethindene Maleate 0.1 %) for topi[INVESTIGATOR_491376],  according to 
drug instructions for use to avoid itching in the injected area .  Benadryl Gel should be applied for 7 
days.  
Use of supplements or complementary medicines/botanicals is prohibited, except for conventional 
multivitamin supplements.  
Study 
Procedure  Study activities upon study entry will include, but not be limited to:  
Informed Consent, full medical history, physical examination, anthropometric measurements, vital 
signs measurements, ECGs, clinical laboratory tests, photography, thermal imaging and skin irritancy 
evaluation of site injection.  
Subjects will be randomized upon eligibility to  RZL -012 or placebo and to a right side or left side 
injection according to a predefined randomization scheme.  
Periodical site visits will allow assessment of treatment safety and efficacy.  
Subjects will be advised to keep their regular diet and physical activity.  
Visit Schedule  
(See Table 2) 
 Subject site visits will be performed ±  1 days from scheduled date  for study visits Day 0 -28 and 2± 1 
days from schedule date for follow -up visits (Day 56 -168).  All data relevant for the visit needs  to be 
obtained within 3 days (e. g., blood tests results) of visit.  
Screening Day 1 visit (Day -28 through -7): 
- Following signing the informed consent - assessment of subject eligibility will include: 
medical history, physical examination, anthropometric measurements (BMI, WHR), vital 

Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  17 CONFIDENTIAL  signs, ECG, serology assays (HBV, HCV and HIV), clinical laboratory tests , drug screen.   
Subjects should come  fasting ( 10-[ADDRESS_631882]) for the glucose  and weight  measurement . 
Clinical laboratory tests will incl ude: 
1. Hematology:  Complete blood count (CBC including White blood cell [WBC] differential 
values) , Fibrinogen, D -dimer, and coagulation (International normalized ratio [INR], Partial 
thromboplastin time [PTT]  and Prothrombin time (PT). ). 
2. Serum chemistry analysis:  sodium, calcium, potassium, phosphorus, glucose, liver 
enzymes (Aspartate aminotransferase [AST], Alanine aminotransferase [ALT], Lactate 
dehydrogenase [LDH], Creatine -kinase MM [CK -MM] , Gamma -glutamyltransferase  
[GTTP], Alkaline  phosphatase [ALP]), Bilirubin, Creatinine, Urea/Blood urea nitrogen 
[BUN[, Total protein, Albumin, Amylase , Creatine phosphokinase [CPK ] and Leptin . 
3. Urinalysis: Nitrite, Sodium, Potassium, Calcium, Phosphate, Protein, RBC, WBC, Blood, 
Glucose, Ketone b odies, Bilirubin, Urobilirubin, Urine specific gravity, Osmolarity, and 
pH. 
- In addition, photography, infra -red imaging and evaluation of skin irritancy by [CONTACT_491401] -lateral area.  
The relevance of RZL -012 for human treatment of obesity will be assessed by [CONTACT_491402] -site thermogenesis, utilizing infra -red imaging.  Thermal imaging with a sensitive (± 0.1  °C) 
Infra -Red thermal camera (FLIR A310) will include:  a view of the injected area and the contra -
lateral non -injected area – at a distance of 1 meter and in a horizontal line from the umbilicus.  The 
thermal camera can create a visual heat map of skin temperatures in real time with a precision of ± 
0.1 °C. 
Screening Day 2 visit (Day -14 through -2):  
- Subjects should come fasting ( 10-12hr. fast) for weight measurement and MRI scan.  
- MRI of 16 slices that include the injected site, for subcutaneous adipose tissue (SAT) 
evaluation.  
- Anthropometric measurements (BMI, WHR) . 
Clinic Admission visi t (Day -1):  
- Subject should come fasting (10-[ADDRESS_631883]) for  weight me asurement  and for laboratory tests 
of: glucose, insulin and lipid profile.  
Lipid profile  will include: Triglycerides [TG], High -density lipoprotein [HDL], Low -density 
lipoprotein [LDL], Total -cholesterol [ TC] and Free fatty acids [FFA] . 
- Inflammatory markers and cytokines – Testing from the 2nd, 3rd and 4th cohorts (on 6 
RZL -012 treated and 2 placebo treated subjects in each cohort):  CRP, Adiponectin, CD -
163, Interleuki n [IL] -1β, IL -4, IL -6, IL -10, IL12p70, IL -13, IL -23, Tumor necrosis factor 
[TNF] α a nd transforming growth factor [ TGF ] β1. 
- Medical history, BMI, WHR, urine drug test, infra -red thermal imaging of the injected area 
and the contra -lateral side . Blood sample  for histamine, serum chemistry and  hematology 
baseline level . 
Baseline visit (Day 0):  
- Baseline visit will be in an in -patient setting .  Subjects will be interned in the study site for 
visit baseline till the following day.  
- Pre-treatment: eligibility confirmation, randomization, vital signs, Draize score,  First blood 
sample for pharmacokinetics will be taken.  
- Treatment - All injections will be administered 45  ° to the skin surface using a 1  mL Luer -
lock syringe and a 30  G x 1/2" needle (the hole of the needle pointing into the fat layer).  
The first injection site will be at [ADDRESS_631884] treatment: ECG (4h and 12h  ± 30min post injection), pulse rate (1h, 2h, 4h, 8h, 12h, 
24h post injection in the opposite hand of blood sampling), vital signs (2h  ± [ADDRESS_631885] 
injection), Draize score  (2h post injection  ± 30 min), adverse events  (AEs) will be recorded 
and pharmacokinetics.  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  18 CONFIDENTIAL  Pharmacokinetics with cohorts 1-4– RZL -012 half -life was determined to be 5  hours in the 
exploratory phase 0 clinical trial (protocol RZL012 -P0US -001.3) , therefore  blood samples will be 
taken after injection at  the given time points: 0, 30, 60 min, 2h, 3h, 4h, 6h, 8h, 12h, 16h,24h, 30h .  
Schedule visits (Day 1-28): 
- Day 1 following treatment will include: ECG, vital signs  including pulse rate , Draize  score, 
photographs and thermal imaging of the treated area.  Las t 2 blood sample for 
pharmacokinetics and blood sample for histamine (24hr ± 2hr following injection) will be 
taken.  
- For safety reasons 24hr ± 2hr following injection, Blood samples for serum  chemistry and 
hematology will be taken  
- Day [ADDRESS_631886] every 7 days ± 1d from treatment till Day 28.  On study vi sit Day [ADDRESS_631887] will come fasting ( 10-12hr fast) for the glucose and lipid profile tests.  During visits 
all tests (physical exam, vital signs, anthropometric measurements, ECG, clinical laboratory 
tests, urinalysis, fastin g glucose and insulin, lipid profile,  FFA, inflammatory markers and 
cytokines, histamine, Draize score, photographs, thermal imaging and MRI will be 
performed according to schedule ( Table 2). 
- Subjects will be questioned for adverse events every visit.  
- Subjects will record their weight following 8-12hr fast (overnight) and at bedtime once a 
week (days 7, 14 and 21)  in a diary.  Diaries will be checked  and data will be  captured in the 
CRFs.  
 
Follow -up visits (Day 29 -168):  
Subjects of the 1st and 2nd cohorts:  
- On visit Day [ADDRESS_631888]  (10-12hr fast) for the glucose, insulin, lipid 
profile tests and FFA levels.  Subjects will be followed up for anthropometric 
measurements, thermal imaging and adverse events.  An MRI scan will be conducted on Day 
[ADDRESS_631889] and 4th cohorts (or treated with the highest dose  achieved):  
-  Will be followed up for anthropometric measurements (e.g., BMI, WHR) every [ADDRESS_631890] ( overnight ) fast and at bedtime once 
a week when not visiting the site,  in a diary.  Diaries will be checked and data will be 
captured in the CRFs.  
- In addition, evaluation of the  injected area and the contra -lateral side will be performed by 
[CONTACT_491403], photographs and thermal imaging  
- Subjects will come fasting (10-12hr fas t) for the glucose,  insulin, lipid profile tests  and FFA 
levels .    
- MRI of 16 slices that includes the injected site (SAT evaluation).  MRI will be conducted on 
Day [ADDRESS_631891] and 4th cohorts . 
- On Day 56 (following MRI), in [ADDRESS_631892] cohort 
([ADDRESS_631893]), an abdominal 
subcutaneous (SC) adipose tissue biopsy will be taken from the injected side .  The b iopsy 
site will be anesthetized with 1% lidocaine and will be performed by a trained medical 
professional .  The sample (an elliptical excision of 15 -20mm deep and 4.5 -6cm long ) will be 
placed in a vial filled with a fixation solution ( formaldehyde ).  After  24h ± 2h, the fixation 
solution should be exchanged to ethanol 80% and further processed for histological analysis .  
Biopsies will be stained f or hematoxylin and eosin  (H&E) and further evaluated for BAT 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631894] cohorts.  Subjects of all other cohort will be 
followed for safety additional 3 months.  
Safety Analysis  Safety data from the study will be summarized descriptively by [CONTACT_139679] c ohort .  Descriptive 
statistics will be calculated for quantitative data and frequency counts and percentages will be 
provided for categorical data.  The nature, frequency, seriousness,  severity and relation to study drug 
of adverse  events (AE) will be tabu lated for all subjects combined and by [CONTACT_3148].  Change -from -
baseline values for vital signs , clinical laboratory and ECG  will be summarized.  Shift tables of 
normal / abnormal versus baseline may be presented as well. Draize scores will be presented in 
tabular format by [CONTACT_765], treatment, and cohort.  Serious adverse events ( SAEs ) will be described in 
narratives as part of the study report.  
Study 
Endpoints  Primary Endpoint : 
Safety: The main objective  is the evaluation of the overall safety of RZL -012 injection into the 
subcutaneous fat.  Therefore, the primary safety endpoint will be the incidence of intolerable side 
effects and all adverse events  of RZL -012 injection into the subcutaneous fat . The dose escalation 
scheme will be stopped if at any dose cohort, 2 patients will experience intolerable side effects . 
Efficacy:  The primary endpoint for efficacy is a sig nificant thermogenesis at the injected site 
compared with the contra -lateral, non -injected site.  This was monitored by [CONTACT_214032] (± 0.1 °C) Infra -
Red thermal camera.  A thermogenic effect is defined by [CONTACT_139648] 1 °C in the injected site when 
compare d to the surroundings and/or the non -injected site, apparent at least 28 days after injection 
and non -related to inflammatory response as determined by [CONTACT_15457].  The primary 
efficacy evaluation will be  supported by [CONTACT_491404], including MRI, biopsy 
and biomarkers.  
Secondary Endpoints : 
1. Duration of the thermogenic effect , defined as a net -delta ≥  1.  
2. Local reduction in fat mass as determined by [CONTACT_9268].  
3. Clinical laboratory changes  from baseline , including improvement in fasting blood glucose and 
lipid profile.  
4. Establishing pharmacokinetic profile for RZL -012. 
5. Anthropometric changes  from baseline , including body weight change.  
6. Elucidation of the histological changes account for the thermogenic effect by [CONTACT_491405].  
7. Change from baseline in  inflammatory markers and cytokines.  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631895] s vehicle control group , for all doses . A maximum of 32 evaluable subjects 
will be included in the study ( 24 in the RZL -012 treatment arm and 8 in the placebo arm) and 
followed for as long as [ADDRESS_631896] on the general applicability of  results from this study.  
If any statistical tests are performed, they will be two -sided .  The required significance level of 
findings will be equal to or lower than 5% .  Nominal p -values will be presented.  
Where confidence limits are appropriate, the conf idence level will be 95%.  
Incidence of intolerable side effects  will be tabulated by [CONTACT_491406] 95% 
confidence intervals . 
The average temperature will be presented in a tabular form by [CONTACT_765], site (treated / not treated) and 
treatment received (RZL -012 / placebo) by [CONTACT_13153] .  Difference between the sites (treated 
– not treated) will be presented in a tabular form by [CONTACT_491407] (net -delta) in these differences by [CONTACT_13153].  
Non-parametric tests will be used to compare the net -delta between the study arms for the relevant 
cohorts and visits.  
AEs and tolerability data will be presented descriptively by [CONTACT_323923] .  AEs will be 
tabulated by [CONTACT_6764], preferred term, se riousness, severity and relation to study drug by [CONTACT_9084].  
Where applicable, changes in values over time (e.g., lab values, vital signs, electrocardiograms 
[ECGs]) will be presented, this will include clinical laboratory evaluations (including CBC, blood 
chemistry and urinalysis), coagulation (INR, PTT , PT), cytokines, vital signs, and ECGs .  Shift tables 
of normal / abnormal versus baseline may be presented as well.  
Draize scores will be presented in tabular format by [CONTACT_765], treatment, and cohort  
Study Du ration  Study duration is 6.[ADDRESS_631897] Bent, Winsconsin  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631898] of adverse health consequences.  Conventional p reventive measures (i.e., diet, 
exercise, behavioral counseling) and current adjunctive pharmacotherapi[INVESTIGATOR_491377].  Few medications are available for the treatment of 
obesity and their treatment s trategies are based on decreasing energy uptake by [CONTACT_491408] .  At present, the only FDA -approved drugs for the 
long-term treatment of obesity are Orlistat (Xenical), L orcaserin (Belviq), and the combination 
of ph entermine and extended -release T opi[INVESTIGATOR_052] (Qsymia) , as well as GLP -1 analogs . 
Orlistat  - blocks the action of pancreatic lipase, reducing triglyceride digestion and, thus, 
absorption .  The drug may reduce absorption of some fat -solubl e vitamins (A, D, E, and K ) and 
beta-carotene, as well as absorption of some medications .  Adverse effects include flatulence, 
fatty/oily stool, increased defecation, and fecal incontinence.  
Lorcaserin  - was approved by [CONTACT_407022] [ADDRESS_631899] to a reduced -calorie diet and 
exercise for long -term weight management in individuals with an initial BMI of 30 kg/m2 or 
higher (obese) or 27 kg/m2 or higher (overweight) with at least 1 weight -related co morbid 
condition (e .g., hypertension, dyslipi[INVESTIGATOR_035], type 2 diabetes mellitus) .  Lorcaserin is a schedule 
IV substance, since it has potential for abuse .  Lorcaserin is thought to decrease food 
consumption and promote satiety by [CONTACT_491409] 5 -HT2C receptors on anorexigenic 
pro-opi[INVESTIGATOR_491378] .  Lorcaserin should be used with caution in 
patients with heart failure, and it has not been studied in patients with serious valvular heart 
disease.  
Liraglutide  - is a glucagon l ike peptide -1 (GLP -1) analog .  GLP -[ADDRESS_631900] to diet and exercise in adults with a BMI of ≥  30 (obese) or adults with a BMI of ≥  27 
(overweight) who have at least 1 weight -related condition (e .g., hypertension, type 2 diabetes, 
dyslipi[INVESTIGATOR_035]).  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631901] to a reduced -calorie diet and exercise for 
long-term weight management in individuals with an initial BMI of 30 kg/ m2 or higher (obese) 
or 27 kg/m2 or higher (overweight) with at least 1 weight -related comorbid condition (e .g., 
hypertension, dyslipi[INVESTIGATOR_035], type 2 diabetes mellitus) .  Topi[INVESTIGATOR_052], which was first licensed as an 
adjunctive antiepi[INVESTIGATOR_321041], has been ass ociated with profound weight loss (an average of 5 -
7% of initial weight) .  The amount of weight loss appears to be greater with higher baseline 
weights .  The exact mechanism of this effect is being actively investigated .  Although the degree 
of efficacy is  exciting, the propensity for adverse effects, especially  the central nervous system  
effects such as drowsiness, paresthesias, memory loss, and confusion, is cause for concern .  
Qsymia contains an extended -release form of topi[INVESTIGATOR_052].  
Collectively,  that the  effect of these medications is limited to 5% - 7% weight loss of the initial 
body weight after 1 year and is associated with significant side effects.  
Bariatric surgery is a drastic intervention, suitable for only a small fraction of the qualifying 
obese population.  Thus, at present, obesity constitutes an outstanding unmet medical need.  The 
World Health Organization has recently released a report on t he significant concerns with 
obesity worldwide that clearly outlines the significant consequences and epi[INVESTIGATOR_491379] (1). 
Obesity is a direct result of food -intake in excess of body energy expenditure.  Therefore, a 
feasible approach to combat obesity is via energy -consuming activities, such as phy sical 
exercise.  Unfortunately, our modern society is moving in the other direction, spending more 
time in immobilized positions, at work and at home.  An alternative strategy for the induction of 
increased energy expenditure is via the activation of brown  adipose -tissue (BAT).  Diametric to 
the common white -adipose -tissue (WAT), which stores energy, BAT burns it.  Thus, BAT -
associated thermogenesis can counterbalance obesity.  For a comprehensive review of the subject 
see reference (2).  BAT existence in humans has only been recently discovered; it is relatively  
scarce and requires hypothalamic hardwiring for its activation, e.g., upon exposure to low 
temperatures.  It was also found that under certain conditions; WAT could give rise to BAT -like 
cells functionally identical to BAT, namely, utilizing fat to produc e heat.  These BAT -like cells 
are called brite or beige adipocytes.  Research labs are currently exploring a variety of 
experimental approaches to BAT or brite/beige activation (3) but none have an FDA -approved 
indication for the treatment of obesity.  
Moreover, it was discovere d that under certain conditions, genuine WAT can become 
thermogenic, independent of BAT -related mechanisms and unrelated to brite/bei ge (cells with 
BAT phenotype, but derived from WAT).  It is well understood that BAT thermogenesis depends 
on up regulation  of uncoupling protein 1 (UCP1).  This protein takes advantage of the proton 
gradient generated by [CONTACT_491410], thereby [CONTACT_491411].  Indeed, UCP1 -defficient mice have defective BAT and are v ery 
sensitive to acute cold exposure.  However, it was also found that if such UCP1 -null mice are 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  23 CONFIDENTIAL  gradually shifted to low temperature, their WAT becomes thermogenic (4).  Moreover, UCP1 -
deficient mice are actually resistant to diet -induced ob esity  (5).  Namely, in the absence of 
UCP1, the mouse is forced to use alternative thermogenic metabolic systems.  However, the 
spectrum of physiolog ical or biochemical stimuli that can lead to such WAT thermogenic 
phenotype, have yet to be explored (6).  Although these studies were carried out in rodents, there 
are indications that WAT conversion into a thermogenic tissue exists in humans (7).  
Raziel Therapeutics has discovered that a novel synthetic molecule can convert WAT into BAT -
like, thereby [CONTACT_491412].  A single injection of this  
compound, called RZL -012, into WAT, is sufficient to trigger outstanding tissue remodeling.  
This chain reaction begins with removal of WAT adipocytes by [CONTACT_179968], with ensuing 
increased vascularization at the treated site and concomitant appearance of  BAT -like adipocytes.  
Temperature measurements of the treated site reveal a persistent local increase in body 
temperature.  
In essence, Raziel Therapeutics technology enables de -novo generation of thermogenic tissue at 
favorable anatomical sites.  Thus, Ra ziel Therapeutics intends to treat obesity via the induction 
of BAT -like thermogenic foci in subcutaneous fat.  As a result, the extra fat accumulated in 
obese persons will be turned into heat.  
The overall clinical plan for RZL -012 includes the completed exploratory ( phase 0) study to 
evaluate the safety, thermogenesis, and pharmacodynamic response to RZL -012.  The additional 
phase 2 study will be initiated to explore higher doses prior to the initiation of larger studies.  
The initial explora tory study ( Study RZL -012-P0US -001.3 ) demonstrated that RZL -[ADDRESS_631902], 5 % RZL -012 in F12 liquid formulation  (RZL -012 in F12 is 5 g/vial, RZL -012 is 
250 mg/vial) was manufactured and packed at Nextar Ltd, Ness -Ziona, Israel.  RZL -012 in F12 
which was once defined as RZL -012 F12 is now defined as RZL -012.  The active ingredient and 
formulation manufacturing and p acking were in accordance with current Good Manufacturing 
Practices (cGMPs).  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  24 CONFIDENTIAL  1.2. NONCLINICAL ASSESSMENTS  
1.2.1.  Pharmacology  
Studies in rats and pi[INVESTIGATOR_296278] -012 triggers remodeling of WAT to BAT -like tissue 
thereby [CONTACT_491413].  The dose of RZL -012 to be  used in clinical trials  was 
extrapolated from the safety data obtained during animal testing  (NOAEL) . 
[IP_ADDRESS].  Efficacy In -vivo and In -vitro Studies  
Nonclinical studies were conducted to prove the efficacy of RZL -012 in several in -vivo and in -
vitro models.  
The in vivo studies (in pi[INVESTIGATOR_159721]) involving local administration of RZL -012, focused on two 
main endpoin ts: fat tissue reduction and conversion of WAT to brown -like adipose tissue, 
measured by [CONTACT_491414], including;  
1. Subcutaneous or epi[INVESTIGATOR_491380] -012 treatment.  
2. Fat tissue remodeling involving non -inflammatory liponecrosis, followed by [CONTACT_59627] 
"browning", where WAT is converted to brown -like adipose tissue.  This conversion can 
be determined by:  
a. Histological fat tissue changes:   While white adipocytes are large and  resemble a 
single large oil drop, with a characteristic condensed nucleus, the cells of brown 
adipose tissue are smaller, contain multiple mitochondria and a euchromatic 
nucleus.  
b. UCP -1 levels:  UCP -[ADDRESS_631903] in WAT.  
3. Assessment of body -surface temperature: Classical brown -like adipose tissue is typi[INVESTIGATOR_491381] (i.e., heat production instead of adenosine triphosphate 
(ATP) ), which can be assessed with an infrared camera that can sense differences in body 
surface temperature.  
The objective of the in -vitro studies was to reveal the mechanism of  action of RZL -012 in 
adipocytes.  Studies were conducted on the 3T3 -L1 adipocytes line, which is considered a model 
for white adipose tissue.  
[IP_ADDRESS].  Safety Pharmacology  
The effect of RZL -012 on the central and peripheral nervous systems was evaluated using the 
Functional Observational Battery (FOB) in male Sprague Dawley rats.  RZL -012 was 
administered subcutaneously to rats (n  = 8/group) as 10 mg/rat.  From the results it was 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631904] of RZL -012 was evaluated on respi[INVESTIGATOR_491382] -out plethysmography.  RZL -012 was administered subcutaneously at a fixed dose of 
10 recorded to cover the entire predetermined time points; Pre -dose, 1, 2, [ADDRESS_631905] any of the parameters tested hence it was concluded that RZL -012 has no 
effects on the respi[INVESTIGATOR_386304] 10 mg/rat.  
A board -certified veterinary cardiologist conducted a qualitative and q uantitative review of the 
electrocardiograms obtained pretest, pre -dose, [ADDRESS_631906] -dose following the 
subcutaneous injection of 500 mg 5.0 % RZL -[ADDRESS_631907] ion of 5.0 % RZL -[ADDRESS_631908] -in-man clinical trial.  An extende d single -dose toxicity 
study was performed according to FDA guidance in two species (rat and pig) to establish the 
NOAEL.  
[IP_ADDRESS].  Extended Single Dose Toxicity Studies  
[IP_ADDRESS].1.  Rats  
Single subcutaneous administration of test item RZL-012 at the doses of 5, 10 , and 20 mg/kg  in 
Sprague -Dawley rats resulted in non -systemic effects and or local effects at the treated skin area.  
Few changes observed in haematological parameters ( WBC count, neutrophils, monocytes and 
eosinophils) were considered secondary effects due to inflamma tory response (local skin 
reactions).  The changes observed in clinical chemistry parameters (increased BUN in males and 
females and increased creatinine and AST levels in females) at all the doses tested and 
histopathological changes in kidneys (necrosis in tubular epi[INVESTIGATOR_2130]) at 20 mg/kg were 
considered systemic effects.  Methods and results from the extended single dose toxicity study 
are described in the Investigator's Brochure.  
Considering skin changes as non-systemic effects and or local effects, the NOAEL was 
determined at 10 mg/rat with an average body weight of 246.[ADDRESS_631909] conditions and doses employed.  
[IP_ADDRESS].2.  Pi[INVESTIGATOR_491383], RZL -012 (50 mg/mL), in domestic Yorkshire crossbred swine following 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  26 CONFIDENTIAL  subcutaneous injection into the subcutaneous abdominal fat on Day  0.  Methods and results from 
the extended single dose toxicity in pi[INVESTIGATOR_491384] s in the Investigator's 
Brochure.  
Assessment of toxicity was based on mortality, clinical observations, body weight, qualitative 
food consumption, body temperature, subcutaneous fat temperature, blood pressure; physical and 
electrocardiographic examination s; and anatomic and clinical pathology.  Blood samples were 
collected and analyzed for porcine stress syndrome testing, histamine level analysis, and 
toxicokinetic assessment of the test article.  
Administration of the test article was not associated with a ny mortality, clinical observations 
(with the exception of transient redness and swelling at injection sites), body weight or food 
consumption changes, effects on electrocardiographic endpoints, or changes clinical chemistry or 
coagulation parameters.  It should be noted that three animals died during the post anesthesia 
recovery period.  The cause of death was considered to be related to perioperative complications 
associated with the anesthesia and not related to RZL -[ADDRESS_631910] article from 
Days 14 -16 until Days 77 -79.  In addition, several animals were observed with perioperative 
hyperthermia and/or hypothermia .  To determine if the perioperative hyperthermia and/or 
hypothermia was caused by [CONTACT_491415] (negative).  
Administration of the test article was associated with changes in subcutaneous fat temperatures, a 
mild increase in neutrophils, and macroscopic and microscopic observations.  
A noticeable difference in subcutaneous fat temperatures was noted between treat ment groups.  
Beginning as early as Day [ADDRESS_631911] article treated sites 
in both males and females.  The increase in temperature was noted through Days  58-63.  At 
study termination, subcutaneous fat temperatures a t treated sites were comparable to vehicle 
control.  
Subcutaneous administration of RZL -012 (50 mg/mL) to farm pi[INVESTIGATOR_491385] [ADDRESS_631912] typi[INVESTIGATOR_491386].  Increases in neutrophils had resolved by [CONTACT_48657] 14 collection.  
Analysis of the plasma samples following subcutaneous administration of RZL -012 (Group  4) 
found that both female and male farm pi[INVESTIGATOR_491387] -012.  Mean systemic exposure 
(area  under the concentration versus time curve between zero and the 24 hour timepoint 
[AUC 0-24hr]) and maximum observed concentration (C max) values, were 3700 (hr*ng/mL) and 
529 (ng/mL), respectively, for males and mean systemic exposure (AUC 0-24hr) and C max values, 
were 2940  (hr*ng/mL) and 528  (ng/mL), respectively, for females.  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631913]-dose.  At 14 days, residual necrotic tissue in the injected areas  was noted with evidence of 
on-going healing characterized by [CONTACT_491416].  There was no evidence of 
systemic toxicity at 24 hours or 14 Days  
The 14 day interim results of this study demonstrated that administration of 5.68 to 7.14  mg/kg 
to males and 5.32 to 6.33 mg/kg to females of RZL -012 (test article) over [ADDRESS_631914] article.  The microscopic changes noted at 24 hours were 
beginning to resolve at 14 da ys.  The results of the final time point at 84 days will allow for 
assessment of the resolution of these findings.  
Based upon the interim results of the study a NOAEL of 7.14 mg/kg in males and 6.33 mg/kg in 
females of RZL -012 has been established in the swine.  The establishment of the NOAEL was 
based upon the microscopic effects being limited to the subcutaneous tissue with no systemic 
effects and the evidence of on -going healing at 14 days.  
1.2.3.  Additional Nonclinical Studies  
• Secondary pharmacology (searchin g for off -target receptors).  
• Establishing pharmacokinetic parameters and investigation of RZL -012 metabolism 
by [CONTACT_491417] (IC 50) in cell -culture.  
• Testing RZL -[ADDRESS_631915].  
• Pyrogenicity in rabbits.  
• Assessment of RZL -012 binding  to the β3 receptor in cellular and nuclear receptor 
functional assays.  
• Assessment of RZL -[ADDRESS_631916].  
• Assessment RZL -[ADDRESS_631917] on 5 -HT neurotransmitter uptake and release in cellular 
and nuclear receptor functional assays.  
• ADME -Toxicology  
• Genotoxicity  
Methods and results from these safety studies are described in the Investigator's Brochure.  
1.2.4.  Clinical Studies  
Raziel Therapeuti cs has conducted an Exploratory  phase 0 , randomized, double -blind, vehicle -
controlled study aimed at the evaluation of safety and thermogenesis -induction of three 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631918] in overweight  and obese  volunteers .  In each cohort , 
8 subjects  were enrolled , 6 active and 2 control .  Study design is presented in the following table:  
Table 1:  Phase 0 Clinical Trial Design  
 Cohort 1  Cohort 2  Cohort 3  
Number of Subjects – Active/Placebo  6/2 6/2 6/2 
Total Dose RZL -012 (mg)  5 10 20 
Dose per NOAEL*  1/50th  1/25th  1/12.5th  
Number of Injections  1 2 4 
 
Primary objective :  Evaluation of the overall safety  and preliminary efficacy  of RZL -[ADDRESS_631919].  
Secondary objective :  Determination of RZL -012 pharmacodynamics  and pharmacokinetics .  
Evaluation of the extent, duration and tissue associated changes of the thermogenic r esponse to 
RZL -012, via minimal invasive means including injected -site thermogenesis imaging, Magnetic 
Resonance Imagin g (MRI) and punch biopsy following injection into the subcutaneous fat. 
Primary Endpoints:  
Safety: The main objective was the evaluation of the overall safety of RZL -012 injection into the 
subcutaneous fat. Therefore, the primary safety endpoint was the incidence of intolerable adverse 
events.  The dose escalation scheme was stopped if at any dose cohort, 2 patients experience d 
intolerable side effects . 
Efficacy:  The primary efficacy endpoint was a significant thermogenesis at the injected site 
compared with the contra -lateral, non -injected site.  This was monitored by [CONTACT_214032] (± 0.1 °C) 
Infra -Red thermal camera.  A thermogenic effect was defined by [CONTACT_139648] 1 °C in the 
injected site when compared to the surroundings and/or the non -injected site, apparent at least 28 
days after injection and non -related to inflammatory response as determined by [CONTACT_378771].  The primary ef ficacy evaluation was supported by [CONTACT_491418], 
including MRI, biopsy and biomarkers . 
Secondary Efficacy Endpoints:  
1. Duration of the thermogenic effect, defined as a net -delta ≥ 1.  
2. Local reduction in fat mass as determined by [CONTACT_9268].  
3. Clinical laboratory changes from baseline, including improvement in fasting blood glucose 
and lipid profile.  
4. Establishing pharmacokinetic profile for RZL -012. 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631920] by [CONTACT_491419].  
7. Change from baseline in inflammatory markers and cytokines.  
Results:  
This was a dose escalation exploratory clinical trial of RZL -012, a first -in-class, new chemical 
entity.  
RZL -[ADDRESS_631921] 
blood levels were seen 14 days following injection .  This elevation was transient (resolved 
within 14  days).  In light of the pre -clinical find ings (increased AST blood levels in female rats 
sacrificed on Day 2 following RZL -012 injection) and in light of the findings in this clinical trial, 
Raziel therefore plans to monitor closely (on 24hr, Day 3, Day 7, Day 14, Day 21, Day 28 and 
will follow f urther if necessary) liver functions in the next clinical trial .  There were no other 
systemic clinically significant AEs.  
The exploration of thermogenesis induction by [CONTACT_296308] -012 in humans was successful.  A raise in 
temperature at the injection site was mos tly evident in cohort 3 (the highest dose) at Day 14 or 
Day 21 following injection in RZL -012 treated subjects only .  This change in temperature was 
captured and recorded by [CONTACT_491420] -red camera.  
Although not statistical significant, a drop in the change from baseline in  Subcutaneous Fat Mass  
(SFM ) ratio (treated/control) over time by [CONTACT_491421] -[ADDRESS_631922] s.  The drop in subcutaneous fat associated with a drop in weight 
(more than 1  kg) and BMI when compared to baseline and is evident in 4 of 6 RZL -012 treated 
subjects of cohort 3 on Day 28 and/or Day 56, while controls gained weight and increased BMI.  
Biopsy did not yield enough tissue (because punch biopsy did not penetrate deep en ough to reach 
the remodeled tissue) , and therefore , it was not possible to demonstrate that thermogenesis is due 
to adipose tissue remodeling by.  
Although not statistical significant, a decrease in TC and FFA blood levels was evident in 
subjects of the RZL -012 treated group in cohort 3 .  This may imply to the mode of action of 
RZL -012 as stimulation of a thermogenic tissue such as BAT, is known to cause a systemic 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631923] via the mobilization of glucose and FFA from the blood stream to feed the ongoing local  
thermogenesis .  Thus, lipolysis of WAT triacylglycerols (TAG) stores is accelerated and the 
uptake of FA derived from blood -born lipoproteins is increased due to the action of lipoprotein 
lipase (LPL).  Raziel assumes that circulating FFA utilization by t he RZL -012-induced 
thermogenic tissue resulted in lower levels of FFA in the blood, a process that may be beneficial 
for health .  There was no consistent pattern to suggest a connection between inflammation 
markers and cytokines levels and changes in therm ogenic activity reflecting the intended effect 
of the drug as opposed to local inflammation and distinguish between events related to M1 and 
M2 macrophages .  Though, an increase in Adiponectin blood level was evident at Day 21 and 
Day 28 in 3 of 6 subjects  treated with RZL -012, but not in controls .  Adiponectin was found to 
be an obligatory mediator of cold -induced browning of WAT (8).  Adiponectin can be elevated 
under various conditions, including those that trigger tissue remodeling in favor of  
thermogenesis such as chronic cold exposure .  Although we do not know what triggered 
elevation of adiponectin in this study , it is known that downstream effects of adiponectin can 
promote the type of tissue remodeling we are expecting.  
Raziel concludes th at the potential risk -benefit balance for RZL -012 is favorable, and that it is 
likely that higher doses of RZL -012 will generate better results .  This will be assessed in the next 
clinical trial  
Method s and results of  this exploratory study are described i n the Investigator's Brochure.  
2. PURPOSE AND STUDY OB JECTIVES  
2.1. PURPOSE  
This phase 2a clinical trial  aims to test safety and efficacy of a new chemical entity, RZL -012, in 
converting WAT into a thermogenic tissue  and reducing fat -mass in overweight and obese males.  
2.2. STUDY OBJECTIVES  
2.2.1.  Primary  
The primary objective is the evaluation of the overall safety and preliminary efficacy of RZL -
[ADDRESS_631924] and the extent, duration 
and tissue associated changes of the thermogenic response to RZL -012, via minimal invasive 
means  (injected -site thermogenesis, MRI and  biopsy) after subcutaneous injection into fatty 
tissue below the s kin. 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631925] dosed 
group, according to schedule, an additional cohort of volunteers will be administrated the next 
dose level.  
Cohort 1: 40 mg RZL -012 (1/6.25t h of the NOAEL determined in the GLP Toxicology studies).  
Cohort 2: 80 mg RZL -012 (1/3.125th of the NOAEL determined in the GLP Toxicology studies).  
Cohort 3: 120 mg RZL -012 (1/2.34375th of the NOAEL determined in the GLP Toxicology 
studies).  
Cohort 4: 180 mg RZL -012 (approximately the NOAEL determined in the GLP Toxicology 
studies).  
3.3. DOSING  
3.3.1.  Dosing Regimen  
The dosing regimen will be a  single dose treatment injection  of RZL -[ADDRESS_631926] 6 subjects randomly assigned to the RZL -012 treatmen t group (cohort 1) will initiate at 
the dose of 40 mg RZL -012 (approximately 1/ 6.25th the NOAEL as determined in the GLP 
toxicology study) and 2 more subjects will be given placebo ( vehicle ). 
If no more than [ADDRESS_631927] , an additional 6 subjects will receive a dose of 
80 mg RZL -012 (approximately 1/ 3.125th of the NOAEL) and 2 more subjects will be given 
placebo ( vehicle ). 
If no more than [ADDRESS_631928] , an additional 6 subjects will receive a dos e of 
120 mg RZL -012 (approximately1/2.34th of the NOAEL) and 2 more subjects will be given 
placebo ( vehicle ). 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631929] , according to schedule an additional cohort of 6 
volunteers, as above, will receive 180 mg RZL -012 ( 1/1.39 of the NOAEL) .  Additional  2 
subjects in the cohort will serve as control and will be inje cted placebo (vehicle).  
Dosing of the first [ADDRESS_631930] at each dose ; nevertheless , the blindness will remain intact.  
The next subjects in the cohort will be randomized to either active treatment or placebo in a ratio 
determined by [CONTACT_491422] .  Dosing of the next subjects will 
be in couple s and the last subjects will be in a triplet.  
If [ADDRESS_631931] experiences intolerable side effects in the lower -dose cohort, and based on the 
decision made by a DSMB .  The decision to proceed to the next cohort will be made  after 
reviewing all safety data collected by [CONTACT_2006] 14 within 2 ± 1d  of the last dosed subject in  each 
cohort .  The DSMB will be comprised of two independent medical doctors ( MDs ) expert in early 
phase clinical trials.  
3.3.2.  Intolerable Side Effect  
Safety will be the principal  primary endpoint  of this study, as such if there are [ADDRESS_631932] defined as any of the following treatment -related adverse drug 
reactions (ADRs):  
• Any Grade 3 or grea ter event except for the following (For the following entities, a 
discussion will be held by [CONTACT_978], DSMB and Sponsor to decide whether considered as an 
intolerable side effects):  
o Flu-like symptoms and fever that responds to standard treatment within72 hours 
o Localized edema and erythema  
o Pruritus  
o Pain 
o Skin/soft tissue inflammation  
o Fat Atrophy  
o Liver enzymes abnormality  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631933] would be any Grade 3  or greater event : 
Clinical Abnormalities  Table  
 
* Erythema – the measured local reaction at the greatest single diameter beyond the injected area surface of all 
injections ([ADDRESS_631934] and fourth cohort), the 
measurement sh ould be recorded as a continuous variable.  
**Induration –– the measured local reaction at the greatest single diameter beyond the injected area surface of all 
injections ([ADDRESS_631935] an d fourth cohort), the 
measurement should be recorded as a continuous variable.  
Liver Enzyme  Abnormalities  Table  
Serum *  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  Potentia lly Life 
Threatening  
(Grade 4)  
Liver Function Tests –ALT, AST 
increase by [CONTACT_12245]  [ADDRESS_631936]  3 – [ADDRESS_631937]  
beyond 10 days  > [ADDRESS_631938], and the actions taken are to be fully documented in source documents and Case Report 
Forms (CRFs).  Local Reaction to 
Injectable Product  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  Potentially Life 
Threatening 
(Grade 4)  
Pain Does not interfere 
with activity 
Repeated use of non -
narcotic pain reliever 
> 24 hours  Interferes with 
activity  Any use of narcot ic 
pain reliever beyond 
7 days following 
injection or prevents 
daily activity  Emergency room 
(ER) visit or 
hospi[INVESTIGATOR_491388]/Redness *  2.5 - 7 cm  7.1 - 15 cm  > 15 cm  Necrosis or 
exfoliative 
dermatitis  
Induration/Swelling 
** 2.5 - 7 cm and does 
not interfere with 
activity  7.1 - 15 cm or 
interferes with 
activity  > 15 cm or prevents 
daily activity  Necrosis  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631939] will be withdrawn from the study, but followed 
for toxicity.  
The study may also be prematurely terminated in any of the following cases:  
• Recurring serious or severe ADR clinically evaluated by [CONTACT_491423].  
• A decision made by [CONTACT_166327]/or IRB/EC and/or local regulatory agency to terminate 
the study.  
4. STUDY ENDPOINTS  
4.1. PRIMARY ENDPOINTS  
Safety: The main objective is the evaluation of the overall safety of RZL -012 injection into the 
subcutaneous fat.  Therefore, t he primary endpoint will be the incidence of intolerable side 
effects and all adverse events of RZL -012 injection into the subcutaneous fat.  The dose 
escalation scheme will be stopped if at any dose cohort, 2 patients will experience intolerable 
side effects . 
Efficacy:  The primary endpoint  for efficacy  is a si gnificant thermogenesis at the injected site 
compared with the contra -lateral, non -injected site.  This was monitored by [CONTACT_214032] (± 0.1 °C) 
Infra -Red thermal camera.  A thermogenic  effect is defined by [CONTACT_139648] 1 °C in the injected 
site when compar ed to the surroundings and/or the non -injected site, apparent at least 28 days 
after injection and non -related to inflammatory response as determined by [CONTACT_378771].  The primary efficacy evaluation will be supported by [CONTACT_491424], including MRI, biopsy and biomarkers .  
4.2. SECONDARY ENDPOINTS  
Following are the study's secondary endpoints:  
1. Duration of the thermogenic effect, defined as a net -delta ≥ 1 , see definition in 
Section  [IP_ADDRESS].1 . 
2. Local reduction in fat mass as determined by [CONTACT_9268], see definition in Section [IP_ADDRESS].2 . 
3. Clinical laboratory changes  from baseline including improvement in fasting blood 
glucose and lipid profile , see definition in Section [IP_ADDRESS].3 . 
4. Establishing pharmacokinetic profile for RZL -012, see definition in Section 6.1.15 . 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  35 CONFIDENTIAL  5. Anthropometric changes from baseline, including body weight change , see definition in 
Section [IP_ADDRESS].[ADDRESS_631940] by [CONTACT_491425], see definition in Section [IP_ADDRESS].5 . 
7. Change from baseline in inflammatory markers and cytokines , see definition in 
Section  [IP_ADDRESS].6 . 
5. STUDY POPULATION  
5.1. INCLUSION CRITERIA  
Subjects meeti ng all of the following criteria will be eligible for study participation : 
1. Adult male  subjects [ADDRESS_631941] is considered overweight  and obese , with 2 7.5 < Body Mass Index (BMI) ≤ 34.9. 
3. Significant subcutaneous abdominal fat as defined by [CONTACT_491426] ≥  0.9. 
4. Subjects with stable weight in the last [ADDRESS_631942]'s declaration: anorexia nervosa, 
bulimia nervosa.  
6. Generally considered healthy according to medical history, physical exami nation, ECG 
and laboratory evaluation with a special emphasis on metabolic parameters (fasting 
glucose concentration <  100 mg,  normal blood pressure).  
7. Subject is willing to refrain from sexual activity or agrees to use a double-barrier 
contraceptive device  (e.g., condom  and spermicide ) for [ADDRESS_631943] sign an informed consent indicating that they are aware of the 
investigational nature of the study.  
5.2. EXCLUSION CRITERIA  
Subjects meeting any of the following criteria will be excluded:  
1. Subjects weighing less than [ADDRESS_631944] reduced/gained weight more than 5 % of their current body weight in 
the last 3 months.  
3. Unable to tolerate subcutaneous injection.  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  36 CONFIDENTIAL  4. Subjects with uncontrolled cardiac, hepatic, renal or neurologic/psychiatric disorders, that 
in the opi[INVESTIGATOR_491375], are not eligible.  
5. Subjects who test positive to Hepatitis B virus (HBV), Hepatitis C virus (HCV), or 
Human immunodeficiency virus (HIV) are not eligible.  
6. Subjects with a clinical history of primary or secondary immunodeficiency, autoimmune 
disease or subjects taking immuno suppressive drugs such as corticosteroids are ineligible.  
7. As a result of medical review, physical examination, the Principal Investigator (PI) (or 
medically qualified nominee) considers the subject unfit for the study.  
8. Medication use on regular basis inclu ding blood and blood products.  
9. Positive drug and alcohol tests.   
10. Known sensitivity to components of the injection formulation.  
11. Prior wound, tattoo or infection in the treated area.  
12. Excessive growth of hair in the abdomen region.  
13. Claustrophobia or MRI incompatible device or implant.  
5.3. SUBJECT IDENTIFICATION  
A unique code numbers will be assigned by [CONTACT_491427]’ names, personal identification numbers, and/or addresses to protect the su bject's 
identity.  The code numbers and initials will be used in lieu of the subject's name [CONTACT_491467]/or other trial related data.  
5.4. REMOVAL, REPLACEMENT OR EARLY WITHDRAWAL OF SUBJECTS 
FROM ASSESSMENT  NOT DUE TO INTOLE RABLE SIDE EFFECTS  
In the first and second cohorts, if only one subject is withdrawn or removed from the study, and 
no more than one subject experience  intolerable side effects , then the subject will not be 
replace d.  If more than one subject is withdrawn or removed from the  study, and more than one 
subject  experience  intolerable side effects , then the subject will be replaced by [CONTACT_491428].  
In the third and fourth cohort, any withdrawal or removal not due to intolerable side effects 
within the first [ADDRESS_631945].  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631946] that he is free to refuse to enter the study or to withdraw 
from the study at any time, for any reason.  
The Informed Consent Form (ICF) approved by [CONTACT_3433] e IRB/EC will contain a description of the 
study’s purpose, procedures, inconveniences and potential risks, and anticipated benefits.  
Prior to a subject’s participation in the trial, an ICF will be signed and personally dated by [CONTACT_491429].  
If a subject is unable to read, an impartial witness should be present during the entire Informed 
Consent discussion.  After the written Informed Consent form is read and explained to the 
subjec t and after the subject has orally consented to participating in the trial and, if capable of 
doing so, has signed and personally dated the Informed Consent form, the witness should sign 
and personally date the ICF.  By [CONTACT_12568], the witness attests  that the information in the 
ICF was accurately explained to, and apparently understood by, the subject and that Informed 
Consent was freely given by [CONTACT_423].  
Prior to participation in the trial, the subject will receive a copy of the signed and dated  written 
ICF.  During participation in the trial, the subject will receive a copy of the signed and dated 
consent form updates and a copy of any amendments to the written information provided to 
subjects.  
The investigator should document in the source dat a that the Informed Consent was signed prior 
to subject's participation in the study and according to the ICH guidelines, as described above.  
6.1.2.  Medical History  
Subjects' medical history should be fully documented at screening Day 1 ( 28 through 7 days prior 
to baseline), to ensure compliance with study inclusion criteria and the absence of circumstance 
mentioned in the exclusion criteria.  Medical history information must include, but not be limited 
to past and present medical conditions, concomitant no n-drug treatments and hypersensitivity to 
drugs.  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  38 CONFIDENTIAL  6.1.3.  Concomitant Medication  
All concomitant medication given 3 months prior to study entry, including blood and blood 
products  dietary supplements, and non -prescription drugs will be listed at screening/baseline.   
Each entry will include the treatment's start date, treatment name (Gener ic), reason for use, 
dosing regimen (dose and frequency of use), route of administration, and stop date (if 
applicable).  The clinical significance of the medication use will be dec ided by [CONTACT_093].  
Study subjects will be routinely questioned for changes in the administration of concomitant 
medication during the trial.  
6.1.4.  Physical Examination  
The investigator (or medically qualified nominee) will conduct a complete physical ex amination 
at screening Day 1 (performed 28 through 7  days prior to baseline).  Clinically significant 
abnormal findings except overweight and obe sity should be discussed with the Sponsor.  
Additional physical examination to assess subject's safety will be p erformed on study visit on 
Day 28.  
6.1.5.  Vital Signs and Measurements  
Subjects' vital signs will be measured at screening Day1 (performed 28 through 7  days prior to 
baseline) in order to ensure compliance with study inclusion criteria.  
Vital signs measurements will include systolic and diastolic sitting position blood pressure, pulse 
rate, respi[INVESTIGATOR_697], and body oral temperature.  
Additional vital signs measurements to assess subject's safety will be performed at baseline visit 
(Day 0) prior to drug injectio n, 2h ± 30min following drug injection, the following day (Day 1) 
after drug injection (24h ± 2h) and on study visits every [ADDRESS_631947]'s safety will be performed at baseline visit 
(Day 0) prior to drug injection and 1h, 2h, 4h, 8h, 12h, 24h following injection in the opposite 
hand of blood sampling.  
6.1.6.  Anthropometric Measurements  
Subjects' anthropometric measurements will be measured at screening Day 1 (performed 28 
through 7  days prior to baseline) in order to ensure compliance with study inclusion and 
exclusion criteria.  Anthropometric measurements will include height, weight, waist 
circumference and hip circumference.  All anthropometric measurements will be measured in the 
morning following 10-12hr fast (overnight) and according to the Center for Disease Control 
(CDC ) Anthropometry Procedures Manual of the National Health and Nutrition Examination 
Survey (NHANES) January 2007 edition (9). 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  39 CONFIDENTIAL  Additional anthropometric measurements  (apart from height)  will be performed at  Screening 
Day 2 before the MRI to ensure compliance with study inclusion and exclusion criteria, at  -clinic 
admission visit (Day -1) and on study visit on Day 28.  In subjects that are followed for over than 
28 days, anthropometric measurements (apart from height)  will be conducted on visit days 
attended at the study site every [ADDRESS_631948] ( overnight ) and at bedtim e. Subjects wi ll be given a diary  to record their 
weight.  
[IP_ADDRESS].  Weight  
Subjects' Weight will be measured in order ensure compliance with exclusion criteria and to 
calculate the BMI and ensure compliance with study inclusion criteria (2 7.5 < BMI ≤ 34.9). 
The subject will be instructed to stand completely still in the center of the scale platform with the 
feet close together hands at the sides and looking straight ahead .  The weight measurement will 
be taken for the electronic readout and is recorded in kilograms to one digit  after the decimal 
point.  
[IP_ADDRESS].  Height  
Subjects' Height will be measured in order to calculate the BMI and ensure compliance with 
study inclusion criteria (2 7.5 < BMI ≤ 34.9). 
The standing height or stature measurement is an assessment of maximal vertical size.  This 
measure is for persons who are able to stand unassisted.  Standing height is measured with a 
fixed stad iometer with a vertical backboard, a fixed floorboard, and movable headboard.  Hair 
ornaments, jewelry, buns, braids and cornrows should be moved or  removed from the top of the 
head in order to measure stature properly.  The subject will be instructed to stand on the 
floorboard with the heels of both feet together, touching the base of the vertical board.  The toes 
are pointed slightly outward at appr oximately a 60 ° angle.  Body weight is evenly distributed 
with both feet flat on the floor.  The technician will check the position of several points of body 
contact [CONTACT_5863].  The first contact [CONTACT_491430], followed by [CONTACT_491431],  the 
scapula or shoulder blades, and finally the back of the head.  Depending on the overall body 
conformation of the individual, all points may not touch.  In such case, the trunk of the body 
should be positioned vertically above the waist with the arms a nd shoulders relaxed.  The head 
should be aligned in the Frankfort horizontal plane.  The head is in the Frankfort Plane when the 
horizontal line from the ear canal to the lower border orbit of the eye is parallel to the floor and 
perpendicular to the vert ical backboard.  Many people will assume this position naturally, but for 
some it may be necessary to make a minor adjustment.  If required the technician may gently tilt 
the head up or down until proper alignment is achieved with the eyes looking straight  ahead.  
Once correctly positioned the headboard is lowered.  The subject is instructed to take a deep 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631949] is positioned firmly on top of 
the head with sufficient pressure to compress the hair.  The measurement will be read in 
centimeter and recorded in meters.  
[IP_ADDRESS].  BMI  
Subjects' BMI will be calculated in order to ensure compliance with study inclusion criteria 
(27.5 < BMI ≤ 34.9) by [CONTACT_491432]:  
BMI = weight (in kilograms)/ (height)2 (in meters)  
BMI will be computed to on e digit after the decimal point  
[IP_ADDRESS].  Waist Circumference  
Subjects' Waist Circumference will be measured in order calculate the WHR to ensure 
compliance with study inclusion criteria (WHR ≥  0.9). 
The subject will be instructed to gather his gown shirt above the waist, cross the arms, and place 
the hands on opposite shoulders.   If necessary, lower the pants and underclothing to slightly 
below the waist.   The technician will stand on the subject’s right side  and will p alpate the hip 
area to locate the right ilium of the pelvis.  With a cosmetic pencil , draw a horizontal line just 
above the uppermost lateral border of the right ilium.   Cross this mark at the midaxillary line  
which extends from the armpit down the side of the torso.   If it is difficult to find the iliac crest, 
such as on subjects with larger waists, then begin inferior to the midaxillary line (toward the 
subject front) and palp ate the ilium upward to the midaxillary line until the uppermost part of the 
bone  is found .  Extend the measuring tape around the waist.  Position the tape in a horizontal 
plane at the level of the measurement mark.  Check that the tape sits parallel to the floor and lies 
snug but does not compress the skin.  Always position the zero end of the tape below the section 
containing the measurement value.  Take the measurement in centimeters to the nearest 0.[ADDRESS_631950] normal expi[INVESTIGATOR_1516] (one digit after the decimal point).  
[IP_ADDRESS].  Hip Circumference  
Subjects' Hip Circumference will be measured in order calculate the WHR to ensure compliance 
with study inclusion criteria (WHR ≥ 0.9). 
The subject will be instructed to stand upright with feet together and weight evenly distributed.  
The buttocks or hip circumference is the only measure that is not taken directly on the skin.  The 
assistant technician stands in front of the subject and ga thers the fabric of the pants.  The thumbs 
and index fingers hold the folded sides of the pants snugly.  This minimizes the amount of 
material included in the measurement and helps to define the maximum protuberance of the 
buttocks when viewed in profile.  The technician is positioned on the right side with eye level at 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631951] 0.1 cm (one digit after the 
decimal point).  
[IP_ADDRESS].  Waist to Hip Ratio (WHR)  
Waist to Hip Rati o (WHR) will be calculated in order to ensure compliance with study inclusion 
criteria (WHR ≥ 0.9) by [CONTACT_491432]:  
WHR = Waist Circumference (in centimeters) / Hip circumference (in centimeters)  
The WHR will be computed to two digits after the decim al point.  
6.1.7.  Serology Assays  
Assays for Hepatitis C virus (HCV), Hepatitis B virus (HBV) and Human immunodeficiency 
virus (HIV) will be conducted at screening Day 1 (performed 28 through 7  days prior to 
baseline) in order to ensure compliance with study inclu sion criteria.  
6.1.8.  Clinical Laboratory Tests  
Clinical laboratory tests will be conducted at screening Day 1 (performed 28 through 7 days 
prior to baseline) in order to ensure compliance with study inclusion and exclusion criteria.  
Additional studies will be c onducted on different study visits according to schedule as written 
below.  Clinical laboratory tests performed on Clinic Admission visit are performed in order to 
establish a baseline except from the following tests that are performed to confirm eligibili ty: 
urine drug screen and clinical significant results that the PI [INVESTIGATOR_491389].  
The maximum total blood volume will be 30  -100 mL per visit.  Every out -of-range value will be 
assessed by a physician and deemed as either clinically significa nt (CS) or clinically not 
significant ( CNS).  Values that represent a change from baseline in subject’s medical status 
according to the laboratory normal ranges will be adequately documented as an adverse event 
(AE) as described in Section 9. 
[IP_ADDRESS].  Hematology  
Hematology tests will be conducted at screening Day 1 (performed 28 through 7  days prior to 
baseline) in order to ensure compliance w ith study inclusion criteria.  Additi onal Hematology 
testing will be conducted to assess subject's safety on -clinic admission visit (Day -1), at 24hr ± 
2h following injection and  on study visit Day -1, 1, 3, 7, 14 and 28 . 
Hematology tests will include Com plete blood count (CBC) (including White blood cells [WBC] 
differential values) and coagulation tests: White blood cells (WBC), Red b lood cells ( RBC ), 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  42 CONFIDENTIAL  Hemoglobin, Hematocrit, Mean corpuscular volume (MCV), Mean corpuscular hemoglobin 
(MCH), Mean corpuscula r hemoglobin concentration (MCHC), R ed cell distribution width  
(RDW), Platelets, Mean platelet volume (MPV), Fibrinogen, D-dimer , International normalized 
ratio (INR), Partial thromboplastin time (PTT)  and Prothrombin time (PT) . 
[IP_ADDRESS].  Serum Chemistry Analysis  
Testing of blood chemistry values will be conducted at screening Day 1 (performed 28 through 7  
days prior to baseline) in order to ensure compliance with study inclusion criteria.  At screening 
Day 1, s ubjects should be notified to come fas ting (10-[ADDRESS_631952]) for fasting glucose , blood 
test.   
Additional fasting g lucose , insulin , leptin,  lipid profile blood tests will be conducted at clinic 
admission visit (Day -1) and on study visit Day 28  and every 28 days during follow -up period .  
Additional Serum Chemistry testing will be conducted at clinic admission visit (Day -1) to 
establish baseline values , 24hr ± 2hr following injection and on study visit Day -1, 1, 3, 7, 14 and 
28. 
Serum chemistry will include:  Sodium, Calcium, Potassium, P hosphorus, Glucose, Liver 
enzymes (Aspartate aminotransferase [AST], Alanine aminotransfer ase [ALT], Lactate 
dehydrogenase  [LDH], Creatine -kinase MM [ CK-MM], Gamma -glutamyltransferase  [GTTP ], 
Alkaline phosphatase [ALP]), Bilirubin, Creatinine, Urea/Blood urea nitrogen [BUN], Total 
protein, Albumin, Amylase , Creatine phosphokinase [CPK ] 
Lipid profile  will include : (Triglycerides [TG], High -density lipoprotein [HDL], Low -density 
lipoprotein [LDL], Total -cholesterol [TC]  and Free -fatty-acids [FFA]) . 
In case of CK -MM >x5 ULN, subjects will undergo clinical assessment for symptoms and 
alternative causes, and renal function will be assessed (including urinalysis).  
[IP_ADDRESS].  Urine Drug Screen  
Urine drug screen will be conducted at screening Day 1 and at clinic admission visit (Day -1) in 
order to ensure compliance with study exclusion criteria .   
Drugs of abuse will include: amphetamines, barbiturates, benzodiazepi[INVESTIGATOR_1651], cannabinoids, 
cocaine, alcohol, opi[INVESTIGATOR_375789], phencyclidine and propoxyphene.  
[IP_ADDRESS].  Inflammatory Markers and Cytokines  
Testing of inflammatory markers and cytokines values from the 2nd, 3rd and 4th cohort s (on 
RZL -012 treated and placebo treated subjects in each coho rt) will be conducted  in order to 
explore the mode of action at clinic admission visit (Day -1)to establish baseline values (4 mL 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631953]).  Additional cytokines testing will be conducted  study visits Day 7, 14, 21 and 
28. 
Inflammatory and cytoki nes will include: CRP, Adipone ctin, CD -163, Interleukin [IL] -1β, IL -4, 
IL-6, IL -10, IL12p70, IL -13, IL -23, Tumor necrosis factor [TNF] α , and TGFβ1.  
Inflammatory and cytokines level will be measured by [CONTACT_491433], called Q -Plex™.  
Q-Plex Arrays are able to measure the concentration of multiple proteins in each sample and to 
quantify cytokines levels.  Blood samples (4 mL) will be centrifuged at 1200 G in 4  ⁰C for 
10 minutes, plasma collected in aliquots (minimum of 2 aliquots of 500 µL ea ch) within 
20 minutes of centrifugation and flash frozen on dry ice .  Processed samples will be frozen in -
80 ⁰C.  Plasma aliquots will be analyzed by [CONTACT_491434].  
[IP_ADDRESS].  Histamine  
Testing of subjects' blood histamine levels will be conducted at clinic ad mission visit (Day -1) 
visit before drug injection in order to establish a baseline ([ADDRESS_631954]).  Additional 
blood histamine levels will be c onducted the day following drug injection (24h ± 2h following 
drug injection), at study visit Day  3 and 14. 
[IP_ADDRESS].  Urinalysis  
Urinalysis will be conducted at screening Day 1 (performed 28 through 7  days prior to baseline) 
in order to ensure compliance with study inclusion criteria and to allow differential diagnosis in 
case of urinary tract associated AE.  Additi onal urinalysis testing will be conducted on study visit 
Day 14 and 28.  
Urinalysis will include: Nitrite, Sodium, Potassium, Calcium, Phosphate, Protein, RBC, WBC, 
Blood, Glucose, Ketone bodies, Bilirubin, Urobilirubin, Urine specific gravity, Osmolarity, and 
pH. 
6.1.9.  ECG  
Subjects' ECG will be performed at screening Day 1 (performe d 28 through 7  days prior to 
baseline) in order to ensure compliance with study inclusion criteria.  ECG is to be performed on 
at least a triplicate of heartbeats for all measurements and will be recorded at a speed of 25 
mm/sec.  Additional ECGs will be p erformed at 4h ± 30min, 12h ± 30min and 24h  ± 2h 
following drug injection (Day 0 -1) and on Days 14  and 28.  
Computerized ECG analysis will include:  Heart rate, Rhythm, PR interval, QRS axis, and QRS 
duration.  QT interval and QTc will be calculated manuall y according to the Bazett formula.  
ECG will be recorded at a standard speed of 25 mm/sec and standard amplitude of 10  mm/mV.  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  44 CONFIDENTIAL  6.1.10.  Draize Score  
Subjects' skin irritancy will be evaluated by [CONTACT_491435] 1 (performed 28 
through 7  days prior to b aseline) in order to establish a baseline to compare following drug 
injection.  
Additional skin irritancy evaluation to assess subject's safety will be performed at baseline visi t 
prior to injection, and on 2h  ± 30min following injection, on the following day 24h ± 2h  after 
drug injection and on study visits Day 7, 14, 21, and [ADDRESS_631955] will continue to be followed 
every 28 days till Draize score i s 0.  If Draize score is 0 for erythema and edema, then subjects of 
these cohorts will be followed for additional 2 months (every 28 days) by [CONTACT_491436].  For the 3rd and 4th cohorts (or the highest dose achieved) Draize  score will be assesse d 
every 28 days during  the follow -up period.  
Skin irritancy observations in the injected sites and contra -lateral sites will be scored using the 
Draize scale for scoring skin reaction:  
Erythema and eschar formation  Edema formation  
No erythema  0 No edema  0 
Very slight erythema (barely perceptible)  1 Very slight edema (barely perceptible)  1 
Well defined erythema  2 Slight edema (edges are well defined by 
[CONTACT_363681])  2 
Moderate to severe erythema  3 Moderate edema (raised approximately 1mm)  3 
Severe erythema (beet redness) to slight 
eschar formation (injuries in depth)  4 Severe edema (raised more than 1mm 
extending beyond area of exposure)  4 
• Total possible erythema score = 4  
• Total possible edema score = [ADDRESS_631956] in the injected area compared to the 
contra -lateral non -injected area will be conducted at screening Day 1 (performed 28 through 7  
days prior to baseline).  Additional photography will be performed at Day 1 (24h  ± 2h following 
drug injection) and on study visits  Day 7, 14, 21, and 28 .  In subjects that are followed for over 
28 days, photographing will be conducted every 28 days.  
Photo graphy with a digital camera will include:  
1. The injected a rea - at a distance of 20  cm and in a horizontal line from the umbilicus.  
2. The contra -lateral non -injected area - at a distance of 20  cm and in a horizontal line from 
the umbilicus.  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  45 CONFIDENTIAL  3. The injected area  and the contra -lateral non -injected area – at a distance of 1  m and in a 
horizontal line from the umbilicus.  
4. The injected area - at 45 degree angle from the camera and in a horizontal line from the 
umbilicus  
5. The contra -lateral non -injected area – at [ADDRESS_631957] in the injected area compared to the contra -lateral non -injected 
area will be conducted at screening Day 1 (performed 28 through 7  days prior to baseline).  
Additional thermal imaging will be performed at clinic admission visit (Day -1), the day 
following drug injection (24h ± 2h following drug injection) and on study visits  Day 7, 14, 21, 
28, and [ADDRESS_631958] and 4th cohort ( or in the 2nd cohort if [ADDRESS_631959] cohort) additional thermal imaging will be conducted every 28 days  for an additional 
maximum period of 5 months . 
Thermal imaging is non -invasive, non -radiating device that passive ly measures the emitting 
infra -red radiation of body surface with a sensitive ( ± 0.1 °C) Infra -Red thermal camera (FLIR 
A310, ISO  9001 -2008 Certified).  Thermal imaging will include:  a view of the injected area and 
the contra -lateral non -injected area – at a distance of 1 meter and in a horizontal line from the 
umbilicus .  Thermal imaging will be performed in a room of 25  ± 1 °C to reduce environmental 
influences on temperature reading according to a detailed written manual.  
6.1.13.  Fat Tissue Imaging: Magnetic Resonance Imaging (MRI)  
Evaluation of Magnetic Resonance Im aging ( MRI) in all cohort s will be conducted  in eligible 
subjects after [ADDRESS_631960]  at screening  Day 2 (performed 14 through 2  days prio r to baseline) and 
on D ay 28.  
For the 2nd cohort an additional MRI scan will be performed on Day 56.  
For the 3rd and 4th cohort (and for the 2nd cohort if subjects experience intolerable side effects in 
the 3rd cohort ) additional MRI scans will be performed every 28 days for an additional maximum 
period of 5 months  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  46 CONFIDENTIAL  MRI scans of the abdomen will be performed using a 1.5 Tesla machine ( General Ele ctric - 
Signa  or Siemens ) using a body coil.  Subjects will be examined after 2-hour fast  in the supi[INVESTIGATOR_491390].   A breath -hold 
technique  will be  used to avoid motion artifacts  when chest and abdomen a re scanned .  MRI 
scans demonstrating fat in the different compartments will be assessed using a MATLAB -based 
program.   Fat tissues of specific anatomical landmarks will be quantified .  In order to calculate 
the fat mass,  16 consecutive slices of 5mm  width will be used : eight  above the umbilicus and 
eight under the umbilicus  (Figure 1).  The scanner will utilize  a 3D modified DIXON 
(mDIXON) imaging technique without gaps  (5mm thickness and  spacing of 5mm), fast -low-
angle shot (FLASH) sequence with a multi -echo two -excitati on pulse sequence for phase -
sensitive encoding of fat and water signals (TR,3.6ms; TE1,1.19ms; TE2,2.3ms; 
FOV  520×440×80mm; 2×1.4×1mm voxel size) .  Sixteen  images of the phanto ms will be  
generated, including in -phase, out -phase, fat and water phase .  Image s should be saved in a 
DICOM format with the information of date, subject's screening number and orientation 
(Left/Right) to be transferred by [CONTACT_1034] 's request for analysis .  MRI  will be performed 
according to a detailed written manual.  
Figure 1:  MRI: Distribution of 16 Consecutive Slices   
 
6.1.14.  Biopsy  
On Day 56 (following MRI), in [ADDRESS_631961] cohort (or the 2nd if 
[ADDRESS_631962] cohort) an abdominal SC adipose tissue 
biopsy will be taken from t he injected side .  The Sponsor or designee will select 3 subjects to go 
under a biopsy: two subjects who will be demonstrating clear t hermogenesis (assuming an 
active) and one subject who will not demonstrate thermogenesis (assuming a control).   Before 
biopsy the Sponsor representative who is un -blinded to the study will confirm that the selected 
subjects are indeed [ADDRESS_631963] biopsy and will terminate their study participation.  

Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  47 CONFIDENTIAL  After local anesthesia , an elliptical excision  biopsy will be conducted by a trained medical 
professional  10 cm lateral to the umbilicus lateral  wall ( Figure 2).  A sample of fat tissue (a 
biopsy of an ellipse of 15 -20 mm deep  and 4.5 -6 cm long, Figure 2) will be taken from the 
incision.  For optimal cosmetic results the incision will be made on a slant following Langer ’s 
lines .  The incision will be stitched appropriately  and the wound will be covered with a bandage 
or sterile dressing.   The sample will be divided in two. One half will be placed in a vial filled 
with a fixation solution ( formaldehyde ).  After 24h ±  2h, the fixation solution should be 
exchanged to ethanol 80% and further processed for histological analysis.  Each vial and lid will 
be labeled with: subject’s name, subject’s identification number and biopsy site.  The other half 
of the biopsy will be embedd ed in a labeled cryomold with Optimum Cutting Temperature 
(OCT) compound and flesh frozen using a  cryostat  or liquid nitrogen . Each sample will be 
labeled with: subject’s name, subject’s identification number and biopsy site. Biopsies will be 
sent to the s ponsor in an adequate manner and evaluated by a certified pathologist .  Biopsies will  
be stained for  hematoxylin and eosin stain  (H&E ) and further evaluated for BAT and other 
markers and morphometry .  
Figure 2:  Biopsy Site  and Dimensions  
 
6.1.15.  Pharmacokinetics  
Testing of RZL -012 Pharmacokinetics will be conducted at the baseline visit till the following 
day (Day 0-1).  Subjects will stay overnight in the study center.  Blood samples (10  mL blood 
per sample in K 2EDTA vials, 100  mL/subject/24h) will be taken after injection at the given time 
points: 0, 30, 60 min, 2h, 3h, 4h, 6h, 8h, 12h, 16h,24h, 30h  in subjects from all cohorts .  Whole 
blood samples (10  mL x12 time points) will be store d on an ice block or wet ice until 
centrifu ged.  Samples will be placed in the centrifuge and spin cycle started within 60 minutes of 
collection.  Samples will be centrifuged at 1200  g in 4 °C for 10  minutes.  P lasma will be 
removed and placed in aliquots (4 aliquots of 1  mL each) within 20 minutes of centrifugation and 
flash frozen on dry ice.  Processed samples will be placed in frozen ( -60 to -90 °C) storage.  
Determination of RZL -[ADDRESS_631964] 
Research Laboratories Ltd.  Samples (2 aliquots/subject/time point) will be sent to Analyst 
frozen on dry ice and 2 aliquots will be retained for possible future analysis.  

Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631965]’s compliance 
record, physical examinations, vital signs measurements, blood testing, and by [CONTACT_491437].  
The trial will proceed within a cohort and from one cohort to the next as long as no more than 
one subject experiences intolerable side effects and based on the decision made by a DSMB .  
Proceeding from one cohort to the next will be based  on the decision made after reviewing all 
safety data collected by [CONTACT_2006] 14 within 2 ± 1d of the last dosed subject in each cohort .  The 
DSMB will be comprised of two independent MDs expert in early phase clinical trials.  
The adverse events reported during t he trial will be graded ( see Section 9), documented , and 
assessed in light of their clinical significance and relation to investigational product.  In addition, 
the following information regarding the AE must be obtained: AE description, start date, end 
date (if applicable) or ongoing, severity, seriousne ss, relationship to study drug,  outcome (e.g. , 
resolved / unresolved), and action taken (e.g. , concomitant medication).  The sponsor or the 
sponsor representative will provide information regarding SAE expectedness based on data 
included in the IB .  Adverse event monitoring will be conducted throughout subject’s 
participation up to [ADDRESS_631966] and 4th cohort (or the 
highest dose achieved) a dverse  events will be recorded after D ay [ADDRESS_631967] did 
not terminate participation in the study.  
6.1.17.  Evaluation of Response  
Evaluation of response will be conducted on Day 7 and every 7 days thereafter till Day 28.  
[IP_ADDRESS].  Evaluation of Pr imary Endpoints  
[IP_ADDRESS].1.  Safety and Tolerability Monitoring  
For determination of the study's primary end point, evaluation of safety and tolerability will be 
conducted according to definitions and guidelines below.  
Safety and tolerability will be assessed by [CONTACT_127345] (e.g. , PI, site coordinator, and 
study nurse) and the study subjects on the basis of the following:  
1. AEs and Serious Adverse Events (SAEs), including severity, relation to study treatment 
and classification by [CONTACT_491438] s comprise intolerable side effects . 
2. Physical exams, Draize score and vital signs measurements.  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631968]’s  weigh t diary . 
[IP_ADDRESS].2.  Efficacy Endpoint – Significant Thermogenesis  
The study primary efficacy endpoint, a significant thermogenesis at the injected site will be 
evaluated by c omparing with the contra -lateral, non -injected site.  A significant thermogenic 
effect is defined as the increase of 1  °C from baseline in the difference in temperature (in °C) 
between the treated and not -treated sites (net delta) .  This thermogenesis shou ld be apparent by 
28 da ys after injection.  The sites temperatures will be measured with a sensitive (± 0.1  °C) 
Infra -Red thermal camera . 
[IP_ADDRESS].  Evaluation of Secondary Endpoints  
[IP_ADDRESS].1.  Sustained Thermogenic Effect  
Sustained thermogenic effect will be evaluated by [CONTACT_491439].  A sustained thermogenic 
effect is defined as an evident thermogenic effect after [ADDRESS_631969] 
is defined as the increase of 1  °C from baseline in the differen ce in temperature (in °C) between 
the treated an d not -treated sites (net delta) .  The duration of the thermogenic effect will be 
evaluated in the lower dose groups till Day 56 and in the higher  dose group s by [CONTACT_491440] 28 days in those subjects  demonstrating clear thermogenesis by 28 days after injection for 
a maximum period of an additional 5 months.  
[IP_ADDRESS].2.  Local Fat Mass Reduction  
Local reduction in fat mass will be evaluated by [CONTACT_9268].  A local fat reduction is defined as a 
significant reduction (compa red to baseline) in the average width of abdominal subcutaneous fat 
in the injected area compared to the contra -lateral area , SFM ratio , as evaluated by [CONTACT_9268] .  Local 
fat reduction in cohort 4 will be defined as a significant reduction (compared to baseline)  in the 
average width of abdominal subcutaneous fat in the injected area compared to the surroundings 
area, SFM ratio , as evaluated by [CONTACT_9268] .  MRI will be evaluated in  all groups at baseline and at 
Day 28 .  MRI will be evaluated in  the cohort 3 (or in cohort  [ADDRESS_631970] cohort) and cohort 4 every 28 days for up to 6 months from 
the beginning of treatment . 
[IP_ADDRESS].3.  Clinical Laboratory Changes  
Clinical Laboratory Changes will be evaluated comparing to baseline.   Clinical laboratory 
changes definition is a significant change from baseline according to the laboratory normal 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631971]’s medical status as assessed by [CONTACT_408482], 
including improvement in fasting glucose and lipid  profile.  
[IP_ADDRESS].4.  Anthropometric Measurements Change  
Anthropometric measurements will be evaluated comparing to baseline.  Anthropometric 
measurements changes are defined as significant reduction in body weight, BMI and WHR at the 
end of the study compared to baseline.  
[IP_ADDRESS].5.  Histological Changes  
Histological changes will be evaluated comparing to known historical data.  Histological changes 
definition is an evident change from known historical data of normal subcutaneous adipose tissue 
as assessed by [CONTACT_491441].  
[IP_ADDRESS].6.  Inflammatory Markers and Cytokines Changes  
To determine drug mechanism of action, inflammatory markers and cytokines level in cohorts 2 
through 4  will be evaluated by [CONTACT_491442].   Inflammatory markers and cytokines  
changes d efinition is a n apparent  change  from baseline.  
[IP_ADDRESS].  Compliance Monitoring  
Compliance monitoring will include the following procedures:  
• Compliance assessment by [CONTACT_296330], including but not limited to 
subject questioning  and review of the weight diary completed by [CONTACT_423] . 
• Completion of weight diary by [CONTACT_423] . 
[IP_ADDRESS].  Dispensing of RZL -[ADDRESS_631972]'s allocation (kits 
received at site, returned kits) will be properly documented, dated and signed in a designated site 
folder to allow full product tracking.  Source documents will be kept for the duration require d by 
[CONTACT_1295] s and ICH -GCP (whichever is longer).  
[IP_ADDRESS].  Questioning of Study Subjects  
Questioning of study subjects during site visits and any unscheduled conversations (e.g. , by 
[CONTACT_648]) with site staff will be fully documented in subject file.  Whenever possible, subject 
questioning should include, but not be limited to, inquiring information regarding occurrence and 
severity of AEs, treatment tolerability and compliance to fut ure scheduled procedures and visits.  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631973]  file. 
Screening visit Day 1 should be performed  no later than 7 days prio r to baseline visit for all 
cohorts .  
Subjects should be notified to come fasting ( 10-[ADDRESS_631974]) fo r the fasting glucose test  and 
weight measurement .  Subjects screening visit D ay 2 should be performed no later than 2 days 
prior to baseline visit .  Subjects who are alternates, and not dosed, the screening visit Day 2 
should be performed no later than 12 -14 days prior to baseline.  
Study screening D ay 1 procedures will include the following:  
• Informed Consent - Section 6.1.1  
• Medical History - Section 6.1.2  
• Concomi tant Medication - Section 6.1.3  
• Physical Examination - Section 6.1.4  
• Vital Signs  and Measurements  - Section 6.1.5  
• Anthropometric Measurements - Section  6.1.6  
• Serology Assays – Section 6.1.7  
• Clinical Laboratory Tests - Section 6.1.8  
• ECG - Section 6.1.9  
• Draize Score – Section 6.1.10  
• Photography  of Injected Site  – Section 6.1.11  
• Thermal Imaging - Section 6.1.12  
• Fasting glucose  
Subjects may be rescreened if they were screened and not dosed within 14 days .  The following  
procedures will be performed: Clinical Laboratory Tests (hematology, serum chemis try, and 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  52 CONFIDENTIAL  urinalysis), vital signs, weight, BMI, waist and hip circumference WHR, Draize score, 
photography and thermal imaging.  
Study screening day 2 procedure will include the following:  
• Anthropometric Measurements - Section 6.1.6  
• Fat Tissue Imaging: Magnetic Resonance Imaging (MRI ) - Section 6.1.13  
6.2.2.  Study Randomization  
Subjects will be randomized to each study group, i.e. , investigational therapy or control, left side 
injection or right side injection according to a predefined randomizat ion scheme.  The 
investigational therapy group will be treated with RZL -012 and the control group will be treated 
with the same formulation (vehicle) as with RZL -012, absent active medication . 
Masking will be used to blind the Investigator regarding random ization, i.e. , assignment to study 
group will be disclosed only after subject eligibility is confirmed and  immediately before 
treatment initiation.  The pharmacist will be unmasked and will be responsible to fill the syringes 
for injection.  
6.2.3.  Study Treatment  
[IP_ADDRESS].  Treatment with RZL -[ADDRESS_631975] supplied as a single dose single treatment injection in 
multiple sites ( 8-48) of injections.  Before injection, subjects will be advised to keep their regular 
diet and physical activ ity. 
The injection dosing regimen and technique is crucial for the therapy safety and efficacy .  
Syringes will be filled by [CONTACT_491443] 0.1 mL RZL -012 or vehicle and the number of 
syringes will be compatible with the number of injecti ons.  All injections will be administered 
diagonally in 45  °, using a 1 mL Luer -lock syringe and a 30  G x 1/2" needle.  
The injection will be administrated randomly into the left or right abdominal subcutaneous fat 
according to the randomization scheme (the hole of the needle pointing into the fat layer).  A grid 
line will be drawn with a makeup pencil in a horizontal plane  5 cm lateral to  the umbilicus lateral 
wall so that it will cut the injected points symmetrically ( Figure 3). 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  53 CONFIDENTIAL  Figure 3:  RZL -[ADDRESS_631976] cohorts one to four (depends on the number of injection sites) tick marks [ADDRESS_631977] 3 
cohorts and 1 cm for the 4th cohort (Figure 4).  The injection sites will be drawn with a makeup 
pencil.   The needle will be inserted into the skin just above the pencil mark in a vertical manner 
towards earth.  The hole of the needle sh ould be pointing into the fat layer .  An attempt to pull 
the plunger should be made before injecting to ensure that  no blood is coming out .  If so, the 
plunger should be pushed down to inject the medicine .  The formulation  is viscose ; therefore , 
resistance  is expected while injecting.  
Figure 4:  Design of the 24 Injection Sites  
 
This study will be performed in a dose escalation manner:  
Cohort 1:  The first 8 subjects randomly assigned to the study group will receive either RZL -012 
(6 subjects) or placebo (2 subjects).  The initial dose of 40 mg RZL -012 (1/ 6.25th the NOAEL ) is 
based o n HED from GLP toxicology study and safety results of the highest dose cohort (20mg 
RZL -012) from phase 0 clinical trial .  Subjects will receive 8 injection s (0.1 mL  in a 2 x4 rows 
cluster ) of [ADDRESS_631978] , according to schedule and following the 
DSMB approval an additional cohort will enter the study.  

Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  54 CONFIDENTIAL  Cohort 2:   The next 8 subjects randomly assigned to the study group will receive either RZL -
012 (6 subjects) or placebo (2 subjects ).  The dose of 80 mg RZL -012 (1/ 3.125th the NOAEL ) is 
based on HED from GLP toxicology study  and safety results of cohort 1 .  Subjects will receive 
16 injections (0.1 mL each in a 4 x4 rows cluster ) adding up to [ADDRESS_631979] , according to schedule and following the DSMB approval an additional cohort will enter 
the study.   
Cohort 3:   The next 8 subjects randomly assigned to the study will receive either RZL -012 
(6 subjects) or placebo ( 2 subjects) .  The dose of 120 mg RZL -012 ( 1/2.34th the NOAEL ) is 
based on HED from GLP toxicology study  and safety results of cohort 2 .  Subjects will receive 
24 injections (0.1  mL each in a 6x4 rows cluster) adding up to [ADDRESS_631980], according to schedule and following the DSMB approval an 
additional cohort will enter the study.  
Cohort 4:  The next 8 subjects randomly assigned to the study will receive either RZL -012 
(6 subjects) or placebo ( 2 subjects) .  The dose of 180 mg RZL -012 ( 1/1.39 the NOAEL ) is based 
on HED from GLP toxicology study  and safety results of cohort 3.  Subjects will receive 
36 injections (0.1 mL each in 9x4 rows cluster)  adding up to 180 mg.  
The decision to proceed to the next cohort will be made by [CONTACT_491444] 14 within 2 ± 1d.  
Each RZL -012 kit contains 1 vial (250 mg/4.8 mL) corresponding to the number of subjects 
receiving treatment in each cohort.  
RZL -012 will be injected on baseline study visit.  
[IP_ADDRESS].  Treatment with Placebo  
Two subjects randomly assigned to the study in every cohort group will be injected placebo , 
which will be a vehicle  control  (tween -80, propylene glycol, benzyl alcohol and water ) in the 
same manner as mentioned above (Section [IP_ADDRESS] ). 
6.2.4.  Baseline Visit  
Baseline visit is defined in the study as Day [ADDRESS_631981] eligibility.  
Subjects will stay overnig ht in the study cente r till 30h + 3h following drug injection.  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  55 CONFIDENTIAL  Screening information may be considered for baseline data if acquired within the adequate 
timeframe as described in  Table 2. 
Table 2:  Subject Information and Timeframes  
Information  Timeframe  Follow -up Timeframe  
Informed Consent Form  Signed prior to any study 
dedicated procedure   
Medical History and Concomitant 
Medications  At screening visit  and at clinic 
admission visit (Day -1)  
Physical examination  At screening Day1 visit and at 
Day 28   
Vital Signs  At screening Day 1 visit and at 
Days 0 (pre and following 
injection), 1, 7, 14, 21, 28   
Pulse rate  At Day 0 ( pre and following 
injection) and at day 1   
ECG  At screening Day 1 visit, at 
Day 0  (following injection) 
and at Days 1, 14, 28   
Anthropometric Measurements: weight, 
height (screening only),  BMI, waist 
circumference , hip circumference  At screening Day 1 visit , 
screening Day 2, clinic 
admission visit (Day -1) and at 
Day 28  Every 28 days.  
On Days 56, 84, 112, 
140, 168  
Weight – measured at home by [CONTACT_491445] ( 8-12h fast) and at bedtime  At Days 7, 14 and 21  Every week when not 
visiting the site  
Draize Score at the Injected Site  At screening Day 1 and at 
Days 0 (pre - and following 
injection), 1, 7, 14, 21, 28  Every 28 days.  
 
Serology assays (HBV, HCV and HIV)  At screening day1 visit    
Urine d rug screen  At screening Day 1 visit a nd at 
clinic admission visit (Day -1)  
Serum chemistry  At screening Day 1, at clinic 
admission visit (Day -1) and at 
Day 1, 3, 7, 14  and 28   
Hematology  At screening Day 1, at clinic 
admission visit (Day -1) and at 
Day 1, 3, 7, 14  and 28   
Fasting Glucose  At screening Day 1   
Fasting Glucose, Insulin, Leptin, Lipid 
Profile and FFA  At clinic admission visit (Day 
-1) and at Day 28  Every 28 days.  
On Days 56, 84, 112, 
140, 168  
Urinalysis  At screening Day 1 visit and at 
Days 14, 28   
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  56 CONFIDENTIAL  Information  Timeframe  Follow -up Timeframe  
Cytokines and inflammatory markers – in 
subjects from the 2nd, 3rd and 4th cohorts  At clinic admission visit (Day 
-1) visit and at Days 7, 14, 21 
and 28  
Histamine  At clinic admission visit (Day 
-1), and at Day  1, 3 and 14   
Pharmacokinetics in subjects from all 
cohorts  At Day 0 -1  
Photography of the Injected Sites  At screening Day 1 visit and at 
Days 1, 7, 14, 21, 28  Every 28 days.  
On Days 56, 84, 112, 
140, 168  
Thermal Imaging  At screening Day 1 visit ,at 
clinic admission visit (Day -
1)and at Days  1, 7, 14, 21, [ADDRESS_631982] 
and 4th cohorts (or in cohort [ADDRESS_631983] cohort)   Every [ADDRESS_631984] and 4th 
cohorts (or in cohort [ADDRESS_631985] cohort)   Every 28 days.  
On Days 56, 84, 112, 
140, 168  
Biopsy – in subjects from the 3rd cohort  or 
in cohort [ADDRESS_631986] cohort   On Day 56  
AE Assessment  At Days 1, 3, 7, 14, 21, 28  Every 28 days  
Cohorts 1 and 2: AE Assessment by [CONTACT_491446] [ADDRESS_631987] site visits will be performed ±  1 days from scheduled date  for study visits Day 0-28 and 
2± 1 days from schedule date for follow -up visits (Day 56 -168).  All data relevant for the visit 
needs to be obtained within 3 days (e.g. , blood tests) of visit.  
Subject s ites visits will include procedures as described in Appendix I - Trial Schedule of Events . 
For site visit that results in study discontinuation, see termination visit  in Section 6.2.6 . 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  57 CONFIDENTIAL  6.2.6.  Termination Visit  
Once study is discontinued, all reasonable measures should be taken to perform a termination 
visit.  Terminati on visit should include all procedures necessary to complete subjects' records:  
AE reporting, any clinical laboratory test needed to evaluate unresolved AEs, evaluation of 
response, recovery of all clinical supplies and compliance diaries, and updating of  subject 
contact [CONTACT_3031].   
6.2.7.  Unscheduled Visit  
Unscheduled visits will be performed upon investigator's discretion, upon Sponsor request to 
redo tests with unusual results or complete missing results and may occur upon subject’s 
decision with no notifica tion in advance.  Unscheduled visits will include any study procedure 
deemed necessary, as described in Section 6.1. 
7. SAFETY CONSIDERATION S AND GUIDANCE FOR I NVESTIGATORS  
Adherence to protocol monitoring procedures along with the following safety guidance will aid 
and promote subject safety.  
7.1. STUDY RESTRICTI ONS REGARDING CONCOMITANT MEDICATIONS  
Subjects may not receive the following medications while on study:  
• Chronic treatment with systemic steroids  or immunosuppressive drugs .  
• Chronic treatment with Non Steroid Anti -Inflammatory Drugs ( NSAIDs ). 
• Any investi gational product other than RZL -012.  
Before dosing, analgesic gels such as Lidocaine or Pramoxine should be used to numb the 
injected site .  An ice pack may be applied on the site of injection following dosing to help reduce 
pain.  At day 3 following bloo d sampling for histamine,  the anti -histamine Benadryl  Gel 
(Dimethindene Maleate 0.1  %) for topi[INVESTIGATOR_491391] .  Benadryl Gel should be applied  for 
7 days.  
Use of supplements or complementary medicines/ botanicals  and high energy supplements or 
drinks  is prohibited, except for conventional multivitamin supplements.  
7.2. SAFETY MEASUREMENTS  
Simple measures may help avoid specific AEs associated with the use of the RZL -[ADDRESS_631988] be  informed of possible AEs that occurred in 
animal studies (rats and pi[INVESTIGATOR_14107]) : 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  58 CONFIDENTIAL  • Any injection site reaction may occur.  Pain, swelling, itching, edema, erythema, 
hematoma etc.  
• Slight transient injection site bleeding following injection may occur.  
• Itching in the injected area may occur, and study subjects should be advised to use an 
antihistamine gel for topi[INVESTIGATOR_491392], wear wide cotton 
shirts, prevent touch with i rritable clothing, avoid scratching and avoid exposure to direct 
sun.  Itching is expected till 7 days following drug injection.  
• Local erythema in the injected area.  
• Local heat in the injection area.  
• Study restrictions regarding concomitant medications are  listed in Section 7.1.  
• The local subcutaneous fat reduction may  appear as a slight dip in the skin surface.  This 
decline may be temporary and transient.  
• Transient increase  (72%)  in the WBC count  by 24  hours following injection , which 
returned to basal level after 14 days .  Probably associated with the inflammatory response 
at the site of injection  and involve neutrophils , monocytes  and eosinophil s.  
• Increased level of BUN  and of creatinine  and minimal single cell necrosis was observed 
in tubular epi[INVESTIGATOR_491393] a dose 
higher [ADDRESS_631989] dose in this study .  All abnormalities were found to be  
reversible by [CONTACT_2006] 14.  
• Increased  AST level  which is most typi[INVESTIGATOR_491394] .  This elevation was found to be reversible by [CONTACT_2006] 14.  
• Transient increase of serum CRP levels (in rats) which returned to the basic level  by 
14 days.  
• Marked irritancy in the injected subcutaneous tissue resulting in coagulation necrosis of 
relatively large areas in the subcutaneous tissue planes acutely.  Necrosis persisted for up 
to 14 days and was accompanied by [CONTACT_491447].  
• Local inflammation (minimal to moderate) with muscle degeneration,  epi[INVESTIGATOR_3915]/dermal 
necrosis (minimal to severe) and parakeratosis (minimal) .  Inflammation observed at 
injection site was also extended to adjacent subcutaneous adipose tissu e.  By 56 days the 
inflammation was minimal , muscle degeneration  was not evident and inflammation to 
adjacent  subcutaneous adipose tissue was present.  
• A slight elevation in body temperatures was noted in male pi[INVESTIGATOR_14107].  
• Sinus tachycardia (in pi[INVESTIGATOR_14107]),  occurring at the [ADDRESS_631990] dosing. 
• In addition, other acceptable treatment to relieve drug -related AE's should be used at 
Investigator's discretion.  
Study subjects must be informed of possible AEs that occurred in clinical studies (phase 0):  
• At the injection site -local and transient: erythema, oedema, pruritus, anesthesia , pain, 
mass ( subcutaneous scar ). 
• Abdominal abscess  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  59 CONFIDENTIAL  • Transient moderate to severe elevation of the liver enzymes: Alanine aminotransferase 
(ALT) and Aspartate aminotransferase (A ST). 
7.3. PREMATURE DISCONTINUATION FROM STUDY  
Study will be prematurely discontinued in any of the following cases:  
• Subject's request.  
• Any life -threatening (i.e. , Grade 4) adverse event may cause prematurely discontinuation.  
• Systemic hypersensitivity reaction may cause prematurely discontinuation.  
• Any G rade [ADDRESS_631991] (defined in Section 9.3) clinically evaluated by [CONTACT_978]  [INVESTIGATOR_1238]/or 
Sponsor as warranting subject discontinuation.  
• Non-compliance: Subject's non -compliance with study proced ures as evaluated by [CONTACT_976] 
[INVESTIGATOR_1238]/or S ponsor as warranting subject discontinuation.  
• Other reasons  regarded by [CONTACT_976] [INVESTIGATOR_296288] 's discontinuation.  
• Premature study termination as described in Section 7.4.   
Subjects who discontinue the study prematurely will be queried whether an adverse event 
contributed to their decision.  
7.4. PREMATURE STUDY TERMINATION  
The study will be prematurely terminated in any of the following cases:  
• Recurring serious or severe ADR (defined in Section 9.1) clinically evaluat ed by [CONTACT_976] 
[INVESTIGATOR_1238]/or S ponsor as warranting study termination.  
• A dec ision made by S ponsor and/or IRB/EC and/or local regulatory agency to terminate 
the study.  
7.5. DEVIATION FROM STUDY PROTOCOL  
The investigator shall not deviate from the study protocol without firs t obtaini ng a written 
approval from the S ponsor, or its official designee, and if applicable, from the local IRB/EC 
according to local regulations.  
In the event of medical emergencies, the investigator shall use appropriate medical judgment and 
will remov e the subject from any imm ediate hazard, then notify the S ponsor or its official 
designee and if applicable, the local IRB/EC, within [ADDRESS_631992] be approved by t he Sponsor or its official designee and the local IRB/EC 
before they can be implemented.   Accordingly, the S ponsor will not assume responsibility or 
liability for any unauthorized deviation fro m or change to the protocol.  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631993] AND VEHICLE SPECIFICATIONS  
8.1. DESCRIPTION OF RZL -012 
RZL -012 investigational drug is intended for a single dose in multiple injections into the 
subcutaneous fat.  The injection dosing regimen and technique is crucial for the therapy safety 
and efficacy . 
8.2. FORMULATION, PACKAGING AND LABELING  
The RZL -012 drug is a ready to use liquid to be injected to the subcutaneous fat, supplied in a 
1 vial kit.  1 vial contains 250 mg/ 4.8 mL RZL -012 in formulation  F12. 
The vehicle  is a ready to use liquid to be injected to the subcutaneous fat, supplied in a 1  vial kit.  
1 vial contains 1  mL of formulation F12. 
8.3. STORAGE AND STABILITY OF RZL -012 AND VEHICLE  
The RZL -012 and vehicle kits will be stored in the site phar macy at monitored room temperature 
conditions (22  ± 7 ᵒC) protected from light.  Storage space will be separate, designated and 
adequately labeled as containing investigational product.  
Stability program of RZL -[ADDRESS_631994]'s expi[INVESTIGATOR_491395] (First In First Out) principals.  
The storage conditions are summarized in Table 3. 
Table 3:  RZL -012 and Vehicle Storage Conditions  
Storage Conditions  Maximal Storage Duration  
Individual vials:  
Room temperature (15 -30 ᵒC) According to expi[INVESTIGATOR_296290].  
* Stability program for RZL -012 is ongoing and site inventory will be managed by [CONTACT_491448].  
 
8.4. DOSAGE, DISPENSING AND ADMINISTRATION OF RZL -012 AND VEHICLE  
8.4.1.  Dosage  
RZL -012 therapy is available in vials of 250  mg/4.8 mL. 
The vehicle is available in vials of 4.8 mL. 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631995] be kept and handled at room temperature.  
The vial should be manually shaken before consumption.  
1 mL Luer -lock syringes with RZL -012 solution should be filled with 30  G 1/2" sterile needle as 
described below:  
• Cohort 1: 8 x 0.1 m L/syringe/subject  
• Cohort 2: 16 x 0.1 mL /syringe/subject  
• Cohort 3: 24 x 0.1 mL/syringe/subject  
• Cohort 4: 36 x 0.1 mL/syringe/subject  
One vial may be used for dosing of two subjects that are dosed together .  Dosing of both subjects  
will be within a maximum of [ADDRESS_631996] was manufactured by [CONTACT_296335] ([LOCATION_003]) and complies 
with cGMP requirements.  Formulation and packi ng was done by [CONTACT_296336] (Israel) and complies 
with cGMP requirements.  
The vehicle was manufactured and packed by [CONTACT_491449] ([LOCATION_003])  and complies with cGMP 
requirements.  
The RZL -[ADDRESS_631997].  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  62 CONFIDENTIAL  9. ADVERSE EVENTS  
9.1. ADVERSE EVENT DEFINITIONS  
9.1.1.  Definition of Adverse Event  (AE)  
An AE is defined as any untoward medical occurrence in a clinical investigation subject 
administered a pharmaceutical product and which does not necessarily have to have a causal 
relationship with this treatment.  An AE can therefore be any unfavorab le and unintended sign 
(including an abnormal laboratory finding, for example), symptom, or disease temporally 
associated with the use of a medicinal product, whether or not considered related to the 
medicinal product.  This definition includes any abnorma lities or anomalies that were not seen at 
baseline or which worsened during the course of the study, if present at baseline.  
9.1.2.  Definition of Serious Adverse Event  
A SAE is defined as any AE occurring at any dose that results in any of the following outcomes:   
• death  
• a life -threatening AE, as defined below  
• subject hospi[INVESTIGATOR_1081]  
• a persistent or significant disability/incapacity  
• a congenital anomaly/birth defect  
• important medical event, as defined below  
A life -threatening AE is any AE that places the subject, in the view of the investigator, at 
immediate risk of death from the reaction as it occurred (i.e., it does not include a reaction that, 
had it occurred in a more severe form, might have caused death).  
An important medical event is an AE that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_6931] a serious AE when, based upon appropriate medical 
judgment, may jeopardiz e the subject and may require medical or surgical intervention to prevent 
one of the outcomes listed above.  It can also include AEs otherwise judged to be serious by 
[CONTACT_491450].  
9.1.3.  Definition of Adverse Drug Reaction  
AEs associate d with the use of investigational product (i.e., probably or possibly related to 
treatment as defined in Section 9.3) are also termed Adverse Drug Reactions (ADRs).  
9.2. ADVERSE EVENT GRADING  
AE will be documented and graded according to the National Cancer Institute  Common 
Terminology Criteria for Adverse Events (CTCAE) v4.03 June 14, 2010) (10).  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  63 CONFIDENTIAL  AE that do not appear in the CTCAE will be gra ded as follows:  
• Mild (Grade 1):  Sign or symptom, usually transient, requiring no special treatment and 
generally not interfering with usual activities.  
• Moderate (Grade 2):  Sign or symptom, which may be ameliorated by [CONTACT_39508], may in terfere with usual activity.  
• Severe (Grade 3):  Sign or symptom that is intense or debilitating and that interferes with 
usual activities and/or requires hospi[INVESTIGATOR_059].  Recovery is usually aided by [CONTACT_491451].  
• Life-threatening or disabling (Grade 4):  Sign or symptom that is Life -threatening or 
disabling.  
• Death (Grade 5):  Death related to AE  
9.3. CA[LOCATION_003]LITY ASSESSMENT OF ADVERSE EVENTS  (AEs)  
All AEs will be evaluated by [CONTACT_491452] -[ADDRESS_631998].  The terms "probable", "possible", "unlikely", or "unrelated" 
refer to the association with the use of the investigational product, as defined  below in Table 4.  
Medical judgment should be used to determine the relationship, considering all relevant factors, 
including pattern of reaction, temporal relationship, confou nding factors such as c oncomitant 
medication, concomitant diseases and relevant history.  
Assessment of causal relationship should be recorded directly in subjects CRF.  
Definition of AEs causality is specified in the table below ( Table 4). 
Table 4:  Definition of Causality  
TERM  DEFINITION  CLARIFICATION  
Unrelated  This category applies to those AEs 
which, after careful consideration, 
are clearly due to extraneous 
causes (disease, environment, etc.)   
Unlikely 
Related  In general, this category can be 
considered applicable to those 
AEs, which after careful medical 
consideration at the time they are 
evaluated, are judged to be 
unrelated to the study procedures/ 
investigational product.  An AE may be considered unlikely related if or when (must 
have two):  
▪ It does not follow a reasonable temporal sequence from the 
study procedures/administration of the investigational 
product.  
▪ It could readily ha ve been produced by [CONTACT_423]’s clinical 
state, environmental or toxic factors, or other modes of 
therapy administered to the subject.  
▪ It does not follow a known pattern of response to the study 
procedures/investigational product.  
Possibly 
Related  This category applies to those AEs 
for which, after careful medical 
consideration at the time they are An AE may b e considered possibly related if or when (at least 
two of the following):  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  64 CONFIDENTIAL  TERM  DEFINITION  CLARIFICATION  
evaluated, a connection with the 
study procedures/investigational 
product administration appears 
unlikely but cannot be ruled out 
with certainty.  ▪ It follows a reasonable temporal sequence from study 
procedures/administration of the investigational product.  
▪ A causal relationship to the experimental treatment cannot 
necessaril y be reasonably excluded and an alternative 
explanation (e.g., concomitant investigational product or 
concomitant disease) cannot be reasonably suggested as 
causing the treatment emergent AE  
▪ It follows a known pattern of response to the study 
procedures/ investigational product.  
Probably 
Related  This category applies to those AEs 
which, after careful medical 
consideration at the time they are 
evaluated, are felt with a high 
degree of certainty to be related to 
the study 
procedures/investigati onal 
product.  An AE may be considered probably related if or when (at least 
three of the following):  
▪ It follows a reasonable temporal sequence from study 
procedures/administration of the investigational product.  
▪ It could not be reasonably explained by [CONTACT_3433] e known 
characteristics of the subject’s clinical state, environmental 
or toxic factors, or other modes of therapy administered to 
the subject.  
▪ It disappears or decreases on cessation or reduction in dose .  
There are important exceptions when an adverse event does 
not disappear upon discontinuation of the investigational 
product, yet investigational product -relatedness clearly 
exists.  
▪ It follows a known pattern of response to the study 
procedures/investigati onal product.  
Definitely 
Related  This category applies to those AEs 
which, after careful medical 
consideration at the time they are 
evaluated, are felt with definite 
certainty to be related to the study 
procedures/investigational 
product.  An AE may be con sidered definitely related if or when all of the 
following apply:  
▪ It follows a reasonable temporal sequence from study 
procedures/administration of the investigational product.  
▪ It could not be reasonably explained by [CONTACT_491453]’s clinical state, environmental 
or toxic factors, or other modes of therapy administered to 
the subject.  
▪ It disappears or decreases on cessation or reduction in dose .  
There are important exceptions when an adverse event does 
not disappear upon discontinuation of the investigational 
product, yet investigational product -relatedness clearly 
exists.  
▪ It follows a known pattern of response to the study 
procedures/investigati onal product.  
*In this protocol Unlikely is deemed as Unrelated.   
9.4. UNEXPECTEDNESS OF ADVERSE DRUG REACTIONS  
An ADR is considered unexpected when its nature or severity is not consistent with the 
applicable product information (i.e., RZL -012 Investigator's Brochure).  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_631999] is terminated from the study ([ADDRESS_632000] dose cohort until 6 months from injection of RZL -012), should be 
captured in the CRF.  AEs should be recorded in the CRF using the medical terminology found 
in the source documentation.  Whenever possible, diagnoses should be given when signs and 
symptoms are due to a common etiolog y. 
Occurrence of any Grade [ADDRESS_632001] warrant clinical evaluation by [CONTACT_491454] 7 calendar days.  
ADRs graded >  [ADDRESS_632002] details for SAE reporting:  
Sharon Perles, sharon.perles@raziel -therapy.com, fax: [ADDRESS_632003] be faxed or emailed to sharon.perles@raziel -therapy.com, fax: [ADDRESS_632004] include SAE general description, 
start date, end date (if applicable), the reason for evaluation as a SAE, basic subject information, 
assessment of the relationship to the investigational product, expectedness, and study therapy 
information.  
Follow -up information, including outcome, and treatment shall be faxed or emailed within 
48 hours.  Source d ocume nts to support the SAE (e. g., discharge summary, test results) shall be 
included in the report.  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_632005] possible date and no later than 
7 calendar days after SAE end date.  In addition to the informat ion described in the initial report, 
this report will include AE  common terminology criteria  (CTC ) description and grading, 
treatment given (if applicable), SAE outcome, an assessment of the relationship to the 
investigational product, and expectedness.  
SAE will be recorded on designated CRF forms in a timely manner and no later than 7 calendar 
days after its end date.  
The PI [INVESTIGATOR_491396]/EC according to applicable local 
regulations and will update the Sponsor.  
9.5.3.  Expedit ed Reporting  
Expedited reporting by [CONTACT_976] [INVESTIGATOR_296292]/EC is warranted for all Suspected Unexpected Serious Adverse 
Reactions (S[LOCATION_003]R), i.e., unexpected SAEs that are considered related to study product as 
defined in Sections 9.1.2 , 9.1.3 , and 9.4).  Additional cases will be communicated by [CONTACT_976] [INVESTIGATOR_296293]/EC via expedited reporting when required by [CONTACT_1295].  
Expedited reports will be submitted to the applicable regulatory authorities by [CONTACT_491455].  
Any pregnancy of a partner of a study male subject after dosing is considered an immediately 
reportable event.  
Such events must be reported within one (1) working day of the investigator becoming aware of 
the event.  Pregnancies shall be followed for the duration of the pregnancy.  It is the PI’s 
responsibility to provide to the Sponsor follow -up information on the outcome of the pregnancy 
including information about any seque lae. 
10. STATISTICAL CONSIDER ATIONS  
10.1. STUDY DESIGN AND OBJECTIVE  
The purpose of this phase 2a study is to find the  tolerated  dose that provides the largest 
thermogenic effect.  
The study is designed as a randomized, doub le-blind, two -arm clinical trial.  Eligible subjects 
will be randomized to receive either RZL -012 or placebo (vehicle).  In this  feasibility study, 
different parameters of efficacy assessment will be measured  in the all dose group s for a 
maximum period of up to [ADDRESS_632006] 2 cohorts in case of 
termination before visit  Day 112 . 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  67 CONFIDENTIAL  10.2. STUDY ENDPOINTS  
10.2.1.  Primary Sa fety Endpoint  
The main objective is the evaluation of the overall safety of RZL -012 injection into the 
subcutaneous fat.  Therefore, t he primary safety endpoint will be the incidence  of intolerable side 
effects and all adverse events  of RZL -012 injection into the subcutaneous fat.  The dose 
escalation scheme will be stopped if at any dose cohort, 2 patients will experience intolerable 
side effects . 
10.2.2.  Primary Efficacy Endpoint  
The primary endpoint for efficacy is a significant thermogenesis at the injected site compared 
with the contra -lateral, non -injected site.  This was monitored by [CONTACT_214032] (± 0.1 °C) Infra -Red 
thermal camera.  A thermogenic effect is defined by [CONTACT_183357] 1 °C in the injected site when 
compared to the surroundings and/or the non -injected site, apparent at least 28 days after 
injection and non -related to inflammatory response as determined by [CONTACT_15457].  
The primary efficacy evaluation will be supported by [CONTACT_491456], 
including MRI, biopsy and biomarkers  
10.2.3.  Secondary Efficacy Endpoints  
Secondary efficacy endpoints include:  
• Duration of the thermogenic effect, defined as a net -delta ≥  1.  
• Local reduction in fat mass as determ ined by [CONTACT_9268].  
• Clinical laboratory changes  from baseline  in: 
o Fasting blood glucose,  
o Triglycerides (TG),  
o High -density lipoprotein (HDL ), 
o Low-density lipoprotein (LDL ),  
o Total -cholesterol (TC), and  
o Free-fatty-acids (FFA). 
• Pharmacokinetic profile for RZL -012. 
• Anthropometric changes  from baseline  in:  
o Body weight , 
o BMI,  
o Waist circumference, and  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  68 CONFIDENTIAL  o WHR.  
• Change from baseline in inflammatory markers and cytokines : 
o CRP,  
o Adiponectin,  
o CD-163,  
o Interleukin (IL)-1β,  
o IL-4, IL -6,  
o IL-10,  
o IL12p70,  
o IL-13,  
o IL-23,  
o Tumor necrosis factor (TNF)  α and  
o TGFβ1 . 
• Elucidation of the histological changes account for the thermogenic effect by [CONTACT_491425].  
10.2.4.  Safety and Tolerability Endpoints  
Safety endpoints  include : 
• Incidence of AEs and SAEs, by [CONTACT_491457].  AEs will be 
coded using MedDRA version 19.1 (or higher) .  
• Physical examination (including Draize score)  
• Vital signs  
• Blood laboratory tests  
• ECG  
10.3. SAMPLE SIZE JUSTIFICATION  
This study is planned as a dose escalation study following a [ADDRESS_632007] s vehicle control group  for the 2 all doses .  A maximum of 32 
evaluable subjects will be included in the study ( 24 in the RZL -012 treatment arm and 8 in the 
placebo arm) and followed for as long as [ADDRESS_632008] dose cohort s for up to 5 months.  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  69 CONFIDENTIAL  10.4. ANALYSIS SETS  
10.4.1.  Safety Analysis Set  (SA)  
The safety analysis set (SA) will consist of all enrolled subjects who received the st udy 
treatment , either  RZL -012 or placebo (exposed population), including subjects prematurely 
withdrawn.  
All enrolled  subjects receiving at least one study drug injection are consid ered evaluable for the 
SA set.  
10.4.2.  Efficacy Analysis Set (EF)  
The efficacy (EF) will consist of all subjects from the SA analysis set without any  major protocol 
violations measured at baseline .  Subjects will be analyzed according to the treatment received.  
10.4.3.  PK (PKA) Analysis Set  
The PK analysis set will consist of al l subjects with no major deviations related to study drug 
administration (e.g., incomplete injection of study drug).  
10.4.4.  Statistical Analysis of Analysis Sets  
The SA analysis set will serve as the principal data analysis set for the analyses of the safety 
endp oints.  
The EF analysis set will serve as the principal data analysis set for the analyses of the efficacy 
endpoints.  
The PK analysis set will serve as the principal data analysis set for the PK analysis.  
10.5. STATISTICAL ANALYSIS  
10.5.1.  General  
Statistical analysis w ill be performed using SAS V9. 4 or higher (SAS Institute, Cary NC, [LOCATION_003]).  
Statistical analyses will be mainly descriptive in nature where study data will be tabulated and 
summarized using the mean, standard deviation or standard error, median, minimum, maxi mum 
and number of subjects by [CONTACT_491458].  For categorical data, results will be 
summarized via a count and percentage by [CONTACT_9084].  The effects of noncompliance, dropouts, and 
covariates, may be assessed to determine the impact on the genera l applicability of results from 
this study.  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  70 CONFIDENTIAL  If any statistical tests are performed, they will be two -sided.  The required significance level of 
findings will be equal to or lower than 5% .  Nominal p -values will be presented.  
Where confidence limits are app ropriate, the confidence level will be 95%.  
10.5.2.  Subject Disposition  
A detailed description of subject accountability including count of subjects included, 
randomized, exposed, completed (i.e. , subjects who complete the study treatment) and 
discontinued along w ith the main reason for discontinuation will be generated for each cohort 
and for all subjects.  All withdrawals from the study, taking place on or after study drug 
injection, will be fully documented in the body of the Clinical Study Report.  
Note that the  actual study duration is for a period of maximum [ADDRESS_632009] to 
the injection .  If a rechecked value is used for baseline, it should be collected under the same 
conditions as for t he planned baseline (e.g., fasting condition).  
Baseline safety data will be presented along with subsequent safety values assessed during or 
after dosing.  
10.5.4.  Primary Safety Endpoint  
The incidence of intolerable side effects will be presented by [CONTACT_491459] 95% exact binomial Confidence Interval (CI).  
The incidence of all adverse events will be presented by [CONTACT_491460] 95% exact binomial Confidence Interval (CI).  
10.5.5.  Efficacy Analysis  
The average temperature will be presented in a tabular form by [CONTACT_765], site (treated / not treated) 
and treatment received (RZL -012 / placebo) by [CONTACT_13153] .  Difference between the sites 
(treated – not treated) will be presented in a  tabular form by [CONTACT_491461] (net -delta) in these differences by [CONTACT_13153].  
Non-parametric  tests will be used to compare the net-delta between the study arms for the 
relevant cohorts and visits.  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_632010], defined as a net -delta ≥  1, will be 
presented by [CONTACT_491462] .  The duration of the thermogenic 
effect after the Day [ADDRESS_632011] at the Day 28 
visit will be presented.  
Subc utaneous Fat Mass (SFM) ratio (treated sites / control sites) averaged over the MRI slices 
will be presented in tabular form by [CONTACT_765], treatment and cohort .  The change from baseline in this 
ratio (in % from the ratio at baseline) will be presented in the same manner, and compared 
between the treatment arms with non -parametric tests.  
Changes from baseline in fasting blood glucose, lipid profile, anthropometric changes, 
inflammatory markers and  cytokines will  be presented by [CONTACT_765], treatment, and cohort.  
Histology results will be presented in tabular form by [CONTACT_3148].  
10.5.6.  Pharmacokinetics (PK) Assessment  
PK profile will be assessed as described below, and presented in a tabular form.  Individual PK  
parameters will also be presented in a listing.  
PK profile will be assessed by: C max, Tmax (time of maximum observed sample concentration) 
and if appropriate AUC values for the test article and from concentration -time data.  
Based on the data, appropriate parameters will be estimated and may include, C 0/Dose and/or 
Cmax/Dose, AUC (Tlast) (area under the concentration -time curve from time zero to the time of final 
quantifiable sample), AUC (0-t) (area under the concentration -time curve from time zero to t, 
where t denotes a specific sample time following dosing), and AUC/Dose.  Based on the data, 
additional secondary parameters will be calculated, if appropriate, and include, AUC INF (area 
under the concentration -time curve from time zero extrapolated to infinit y), and T 1/2 (terminal 
half-life).  
10.5.7.  Safety and Tolerability  
Safety analyses will be descriptive in nature.  
All reported adverse events will be coded to a standard set of terms using MedDRA coding 
dictionary  (V19.1 or higher)  treatment .  
AEs and tolerabilit y data will be presented descriptively by [CONTACT_323923] .  AEs will be 
tabulated by [CONTACT_6764], preferred term,  seriousness,  severity and relation to study drug by 
[CONTACT_9084].  Where applicable, changes in values over time (e.g. , lab values, vital signs , 
electrocardiograms [ ECG s]) will  be presented, this will include clinical laboratory evaluations 
(including CBC, blood chemistry and  urinalysis), coagulation (INR, PTT, PT), cytokines, vital 
signs, and ECGs .  Shift tables of normal / abnormal versus basel ine may be presented as well.   
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  72 CONFIDENTIAL  Draize scores will be presented in tabular format by [CONTACT_765] , treatment, and cohort.  
10.6. HANDLING OF MISSING DATA  
No imputation of missing data will be performed.  
10.7. INTERIM ANALYSIS  
An interim analysis is planned at the end of each cohort for evaluation of efficacy. For this 
purpose, a data lock (except for externally collected data such as PK) will be implemented after 
each cohort is completed. Upon lack of trends in efficacy due to effect size, t he Sponsor will 
consider study termination.  
11. DATA COLLECTION, STU DY MONITORING, AND D ATA DISCLOSURE  
11.1. DATA COLLECTION AND REPORTING  
Each study subject will be assigned an individual  CRF  that will contain all of the relevant study 
information.  The investigator shall ensure that all data is completely and accurately recorded on 
the CRF s throughout trial duration.  
Data reported on the CRF, that are derived from source documents, should be  consistent with the 
source documents or the discrepancies should be explained.  
All fields and blanks in the CRF s will be completed.  The following abbreviations are to be used 
when values or answers are not available: NA  = Not applicable, ND  = Not done, UNK  = 
Unknown, CONT  = Continued.  
White -out or erasure on the CRF is not permitted under any circumstances.  Any change or 
correction to a CRF should be dated, initialed, and explained (if necessary) and should not 
obscure the original entry (i.e. , an audi t trail should be maintained).  If an entry on a CRF form is 
changed, the correction will be made as follows:   A single line will be drawn through the 
incorrect entry, the date and initials of the reporting individual will be added beside the entered 
chang e and/or correction, and an explanation will be added when applicable.  
When a subject withdraws from the study, regardless of cause, all final study evaluations should 
be attempted.  
If a subject is lost to follow -up, (i.e. , fails to return for scheduled visits) every reasonable effort 
must be made to contact [CONTACT_296346].  All 
actions taken in this regard will be documented and dated in the CRF.  
Once completed, a copy of each completed CRF will be sig ned and dated by [CONTACT_1720] a 
designated represent ative and submitted to the S ponsor.  
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_632012] KEEPI[INVESTIGATOR_296294], laboratory 
reports, informed consent forms, safety reports, s ubjects' CRF, and any other pertinent data.  All 
records are to be retained by [CONTACT_1732] a period of fifteen years after completion of the 
study.  
11.3. SOURCE DATA AND SOURCE DOCUMENTS  
ICH-GCP defines source data as all information in original records  and certified copi[INVESTIGATOR_163503], observations, or other activities in a clinical trial necessary 
for the reconstruction and evaluation of the trial.  Source data are contained in source documents 
(original records or certifie d copi[INVESTIGATOR_014]).  
Source documents are defined as original documents, data, and records (e.g., hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory notes, subject files, and records kept at departments 
involved in the clinical trial, etc.).  
The following da ta is to be recorded directly on the RZL -012 trial forms or CRF which will be 
considered to be the source data:  
• Subjects' weight  diaries.  
• Subjects' questioning,  e.g., pain, itching, topi[INVESTIGATOR_296295].  
• Assessment of AEs relation to investigational product, i.e. , causality assessment, and 
expectedness reported by [CONTACT_1697].  
The investigator should maintain the trial's essential documents as required b y ICH -GCP 
guidelines and the applicable regulatory requirements, and take measures to prevent accidental or 
premature destruction of these documents.  
Upon request of the monitor, auditor, IRB/EC, or regulatory authority, the investigator will 
ensure direc t access all requested trial -related records . 
11.4. STUDY MONITORING  
Monitoring procedures are required to assure compliance to ICH -GCP guidelines, the study 
protocol and local regulations.  
The investigator shall allow the S ponsor or its official designee to monitor and audit periodically, 
at mutually convenient times, all  CRF and corresponding subject records .  The monitoring 
schedule will be based on S ponsor’s mo nitoring plan and  will be done by [CONTACT_296347]’s designee such as CRO . 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_632013]’s initials (first letter of first name [CONTACT_296353]) will identify the subject 
and must be included on all CRF s.  The investigator will complete subject identification on  a 
confidential site log, which will be used for subjects' traceability and follow -up.  
Individual subject medical information obtained as a result of this study is to be considered 
confidential and disclosure to third parties other than the regulatory aut horities, or other persons 
or organizations designated by [CONTACT_941] S ponsor, is prohibited.  Any medical information may be 
provided to the subject’s personal physician or to appropriate medical personnel responsible for 
the subject’s care.   Additionally, data g enerated from this study is to be provided, upon request, 
to the S ponsor’s monitors, as well as to the local IRB/EC.  Subject confidentiality is to be further 
assured by [CONTACT_296348].  
All informati on supplied by [CONTACT_296349]. in connection with this study and not 
previously published, is considered confidential information.  This information includes, but is 
not limited to, the Investigators' Brochure, clinical protocol, CRF,  and other sc ientific data.  Any 
data collected during the study are also considered confidential.  This confidential information 
shall remain the sole property of Raziel Therapeutics Ltd, shall not be disclosed to others without 
the written consent of the Sponsor, and  shall not be used except in the performance of this study.  
The information developed during the conduct of this clinical study is also considered 
confidential, and will be used by [CONTACT_296350].  
The inform ation may be disclosed as deemed necessary by [CONTACT_1034].  To allow the use of the 
information derived from this clinical study, the investigator is obliged to provide Raziel 
Therapeutics Ltd . with complete test results and all data developed in this stud y.  
The S ponsor has full ownership of the original case report forms completed as part of the study.  
By [CONTACT_218268], the investigator agrees that the results of the study may be 
used for the purposes of national and international r egistration, publication, and information for 
medical and pharmaceutical professionals.  The authorities will be notified of the investigator's 
name, address, qualifications, and extent of involvement.  
The information obtained during this study may be mad e available to other investigators who are 
conducting similar studies.  
It is agreed that, consistent with scientific standards, publication of the results of the study shall 
be made only as part of a publication of the results obtained by [CONTACT_491463].  
Raziel Therapeutics Ltd. will disclose the results of the trial on the basis of the final analysis and 
following the revision of a draft manuscript by [CONTACT_473], unless posting would 
compromise publication in a peer -reviewed med ical journal or contravene national laws or 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.[ADDRESS_632014] submissions 
at professional scientific meetings.  
12. HUMAN SUBJECTS  
12.1. DECLARATION OF HELSINKI  
Both the PI [INVESTIGATOR_17446] S ponsor will ensure  that the study is conducted in agreement with the 
Declaration of Helsinki, ICH Guideline for Good Clinical Practice (ICH -GCP), and the local 
laws and regulation.  
12.2. INFORMED CONSENT  
As described in Section 6.1.1 . 
12.2.1.  LIABILITY AND INSURANCE CONDITIONS  
Raziel Therapeutics Ltd. holds a clinical trial liability insurance policy.  
A copy of the policy summary will be filled in the investigator's site file. 
13. REFERENCES  
1. WHO. Obesity and overweight 2013 [Available from: 
http://www.who.int/mediacentre/factsheets/fs311/en/index.html.  
2. Cannon B, Nedergaard J. Nonshivering thermogenesis and its adequate measurement in 
metabolic studies. The Journal of experimental biology. 2011;214(Pt 2):242 -53. 
3. Giralt M, Villarroya F. White, brown, beige/brite: different adipose cells for different 
functions? Endocrinology. 2013;154(9):2992 -3000.  
4. Ukropec J, Anunciado RP, Ravussin Y, Hulver  MW, Kozak LP. UCP1 -independent 
thermogenesis in white adipose tissue of cold -acclimated Ucp1 -/- mice. The Journal of biological 
chemistry. 2006;281(42):[ZIP_CODE] -908. 
5. Liu X, Rossmeisl M, McClaine J, Riachi M, Harper ME, Kozak LP. Paradoxical resistance to 
diet-induced obesity in UCP1 -deficient mice. The Journal of clinical investigation. 
2003;111(3):399 -407. 
6. Kozak LP, Anunciado -Koza R. UCP1: its involvement and utility in obesity. International 
journal of obesity. 2008;[ADDRESS_632015] 7:S32 -8. 
7. Huttunen P, Hi rvonen J, Kinnula V. The occurrence of brown adipose tissue in outdoor 
workers. European journal of applied physiology and occupational physiology. 1981;46(4):339 -
45. 
Raziel Therape utics , Ltd.  Protocol RZL -012-P2aUS -001.4 
RZL -012  Version: 1.4 
 
26 May 2017  76 CONFIDENTIAL  8. Hui X, Gu P, Zhang J, Nie T, Pan Y, Wu D, et al. Adiponectin Enhances Cold -Induced 
Browning of Subcutaneous Adipose Tissue via Promoting M2 Macrophage Proliferation. Cell 
metabolism. 2015;22(2):279 -90. 
9. CDC. Abthropometric Procedure Manual of the National Health and Nutrition Examination 
Survey 2009 -2010 [Available from: http://www.cdc.go v/nchs/nhanes/nhanes2009 -
2010/current_nhanes_09_10.htm.  
10. NIH. Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 2010 
[Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -06-
14_QuickReference_8.5x11.pdf.  
 
Raziel Therapeutics , Ltd.  Protocol RZL -012-P2aUS -001.3 
RZL -012  Version: 1.3 
 
26 May 2017  77 CONFIDENTIAL  Appendix I:  Trial Schedule of Events  
Study Procedure  Screening 
Day 1  Screening 
Day 2  Clinic 
Admission  Baseline  
(Treatment)  Visit Schedule (Days 1 to 28)  Follow -up 
Schedule for 
the highest 
dose cohorts l 
(Days 29 - 168) 
Study Daya Daya-(-
28) 
through 
Day ( -7) Daya-(-14) 
through 
Day ( -2) Day ( -1) Day a 0 Day 1  Day 3  Day 7  Day 14  Day 21  Day 28  Day 56, 84, 
112, 140, 168  
Signed informed 
consent  X           
Medical history  X  X         
Complete physical 
exam  X         X  
Serology assays 
(HBV, HCV, HIV)  X           
Fasting glucose  X  X         
Fasting glucose, 
insulin, leptin and 
lipid profile 
(including FFA)    X       X Every [ADDRESS_632016] 
and 4th  cohorts b   X    X X X X  
Photography of site of 
injection and 
contralateral  X   
 X  X X X X Every 28 days  
MRI section around 
the umbilicus   X        X  
MRI section around 
the umbilicus  – for 
cohort 2     
       On Day 56  
Raziel Therapeutics , Ltd.  Protocol RZL -012-P2aUS -001.3 
RZL -012  Version: 1.3 
 
26 May 2017  78 CONFIDENTIAL  Study Procedure  Screening 
Day 1  Screening 
Day 2  Clinic 
Admission  Baseline  
(Treatment)  Visit Schedule (Days 1 to 28)  Follow -up 
Schedule for 
the highest 
dose cohorts l 
(Days 29 - 168) 
Study Daya Daya-(-
28) 
through 
Day ( -7) Daya-(-14) 
through 
Day ( -2) Day ( -1) Day a 0 Day 1  Day 3  Day 7  Day 14  Day 21  Day 28  Day 56, 84, 
112, 140, 168  
MRI section around 
the umbilicus – for 3rd 
and 4th cohort or in 
cohort [ADDRESS_632017] 
experience intolerable 
side effects in cohort 
3)    
       Every 28 days  
Anthropometric 
measurements: 
(weight, height) BMI, 
(waist & hip 
circumference) WHR  X X X       X Every 28 days  
Weight – by [CONTACT_205504] –
morning( 8-12hr 
overnight fast) and 
evening     
   X X X  On weeks when 
not visiting the 
site 
Urine Drug Screen  X  X         
Infra -Red thermal 
imaging of the 
injected site  X  X  X  X X X X On Day 56  
Raziel Therapeutics , Ltd.  Protocol RZL -012-P2aUS -001.3 
RZL -012  Version: 1.3 
 
26 May 2017  79 CONFIDENTIAL  Study Procedure  Screening 
Day 1  Screening 
Day 2  Clinic 
Admission  Baseline  
(Treatment)  Visit Schedule (Days 1 to 28)  Follow -up 
Schedule for 
the highest 
dose cohorts l 
(Days 29 - 168) 
Study Daya Daya-(-
28) 
through 
Day ( -7) Daya-(-14) 
through 
Day ( -2) Day ( -1) Day a [ADDRESS_632018] 
and 4th cohort or in 
cohort 2 if 2 subjects 
experience intolerable 
side effects will in 
cohort 3)k    
       Every [ADDRESS_632019] 
e X       
Adverse event 
assessment      X------------------------------------------------- → Every 28 days  
Raziel Therapeutics , Ltd.  Protocol RZL -012-P2aUS -001.3 
RZL -012  Version: 1.3 
 
26 May 2017  80 CONFIDENTIAL  Study Procedure  Screening 
Day 1  Screening 
Day 2  Clinic 
Admission  Baseline  
(Treatment)  Visit Schedule (Days 1 to 28)  Follow -up 
Schedule for 
the highest 
dose cohorts l 
(Days 29 - 168) 
Study Daya Daya-(-
28) 
through 
Day ( -7) Daya-(-14) 
through 
Day ( -2) Day ( -1) Day a 0 Day 1  Day 3  Day 7  Day 14  Day 21  Day 28  Day 56, 84, 
112, 140, 168  
Adverse event 
assessment by [CONTACT_491464] 1 and 2     
       On Day 84 and 
112 
Subjects diary 
recording weight     
   X X X  On weeks when 
not visiting the 
site 
Biopsy – 
In subject of cohort 3 
(or in cohort 2 if 2 
subjects experience 
intolerable side 
effects in cohort 3)k,l    
       On Day [ADDRESS_632020] and 4th cohorts (on 6 RZL -012 treated and 2 placebo treated subjects in each cohort) : CRP, Adiponectin, CD -163, 
Interleukin [IL] -1β, IL -4, IL -6, IL -10, IL12p70, IL -13, IL -23, Tumor necrosis fa ctor [TNF] α and TGFβ1.  
c. CBC, coagulation, serum chemistry analysis, renal and liver function , urinalysis, CPK, amylase measurement: before injection ,14d and 28d following injection  
d. Histamine blood level measure ment: clinical admission , following drug injection ( 24h ± 2h) , 3d and 14d following injection  
e. Pre/post – refers to before/after injection respectively  
f. Pharmacokinetics at the given time points: 0, 30, 60 min, 2h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 30h  in subjects from all cohorts . Pharmacokinetics wi ll not be conducted in the 
fourth cohort as the injected dose is divided in 2 clusters 2 weeks apart . 
g. Draize score evaluation: before injection, 2h, 24h and 7d,14d,21d and 28d following injection  
h. Vital signs measurement: before injection, 2h, 24h and 7d,14 d,21d and 28d following injection  
i. ECG is to be performed in triplicate for all measurements in given time point:  4h, 12h, 24h , Day 14 and 28  following injection  
j. Pulse rate measurements at given time points:  1h, 2h, 4h, 8h, 12h, 24h following injection in the opposite hand of blood sampling  
k. For [ADDRESS_632021] s of cohort 3 (in cohort 2 if 2 subjects experience intolerable side effects in cohort 3)  - if thermogenesis is evident by [CONTACT_491465] D ay 56, biopsy from the 
injected for histology and BAT characterization . 
l. For subjects from the 3rd (or in cohort [ADDRESS_632022] cohort) and 4th cohort  
 